Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 1Title Page
A PHASE 1, RANDOMIZED, OPEN-LABEL STUDY IN HEALTHY 
PARTICIPANTS TO ESTIMATE THE BIOAVAILABILITY OF TWO NEW 
ENCORAFENIB FORMULATIONS RELATIVE TO THE CURRENT
FORMULATION AND TO EVALUATE THE EFFECT OF A PROTON-PUMP 
INHIBITOR ON ENCORAFENIB PLASMA PHARMACOKINETICS
.
Study Intervention Number: PF-07263896
Study Intervention Name: Encorafenib
US IND Number: 111003
EudraCT Number: N/A
ClinicalTrials.gov ID:  Not Available
Pediatric Investigational Plan Number: N/A
Protocol Number: C4221024
Phase: 1
Brief Title: A Phase 1 Relative Bioavailability Study Evaluating two new Encoraf enib
Formulations
This document and accompanying materials contain confidential i nformation belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these  documents, you agree to hold this 
information in confidence and not copy or disclose it to others  (except where required by applicable law) or 
use it for unauthorized purposes. In the event of any actual or  suspected breach of this obligation, Pfizer 
must be promptly notified.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Amendment 1 27 June 2022
Original protocol 05 May 2022
This amendment incorporates all revisions to date, including am endments made at the 
request of country health authorities and IRBs and any global p rotocol administrative change 
letter(s).
Protocol Amendment Summary of Changes TableAmendment 1 (27 June 2022)Overall Rationale for the Amendment: In response to the COVID-19 pandemic, COVID-
19 assessments were incorporated into the protocol template to minimize risk for participants 
and staff. PCRUs have now changed their COVID-19 procedures to not re quire testing and 
temperature checks at screening. This amendment is designed to up date the protocol based on 
the new PCRU COVID-19 procedures.
Section # and 
NameDescription of 
ChangeBrief Rationale Substantial or 
Nonsubstantial
Table 1 Periods 1, 2 and 3COVID-19 test 
removed at screening Updated to 
accommodate new COVID-19 Guidelines at the PCRU that no longerrequire COVID-19 testing at screening. Substantial
Table 1 Periods 1, 2 
and 3Temperature check 
removed at screening Updated to 
accommodate new COVID-19 Guidelines at the PCRU that no longer require a temperature check at screening. Substantial
Section 5.2 
Exclusion CriteriaUpdated language 
to exclude participants with a positive COVID-19 test at first admissionUpdated to 
accommodate new COVID-19 Guidelines at the PCRU that no longer require COVID-19 testing at screening. Substantial
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 3Section # and 
NameDescription of 
ChangeBrief Rationale Substantial or 
Nonsubstantial
Section 8.3.5 COVID-19 Specific AssessmentsCOVID-19 test 
removed at screeningUpdated to 
accommodate new COVID-19 Guidelines at the PCRU that no longer require COVID-19 testing at screening. Substantial
Section 5.3.2 Meals 
and Dietary RestrictionsSection was 
updated to align with exclusion criterion 6 on restrictions of food/drink that can be taken before encorafenib dosing. Changed to correct 
protocol inconsistency. Nonsubstantial
Section 6.1.1 
Administration Rabeprazole 
formulation was mistakenly noted as a capsule and was changed to a tablet.Rabeprazole will be 
administered as a tablet at the PCRU.Nonsubstantial
Table 1 Periods 1, 2 
and 3Reference updated Table referenced the 
wrong section of the 
protocol.Nonsubstantial
Section 9.5 Sample 
Size Determination90% confidence 
intervals for AUC
inf and C max 
were estimated based on 9 participants instead of 18.Nine participants 
were required for the PPI drug-drug 
interaction of the 
study. However, the 90% CIs were calculated for 18 participants instead of 9 participants. Thus, the 90% CI data were updated based on 9 
participants.Nonsubstantial
Table 9 Confidence 
Interval Estimation of PK Endpoints for PPI Effect90% confidence 
intervals for AUC
inf and C max 
were estimated 
based on Nine participants 
were required for the PPI drug-drug interaction of the study. However, in Nonsubstantial
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 4Section # and 
NameDescription of 
ChangeBrief Rationale Substantial or 
Nonsubstantial
9 participants instead of 18.Table 9, the 90% CIs 
were calculated for 18 participants instead of 9 participants. Thus, the 90% CI data in Table 9 were updated based on 9 
participants.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 5TABLE OF CONTENTS
LIST OF TABLES................................................. ............................................................... ...10
1. PROTOCOL SUMMARY............................................ .......................................................11
1.1. Synopsis .................................................. ............................................................... .11
1.2. Schema .................................................... ............................................................... .17
1.3. Schedule of Activities .................................... .........................................................18
2. INTRODUCTION ................................................ ............................................................... 23
2.1. Study Rationale ........................................... ............................................................23
2.2. Background ................................................ .............................................................24
2.2.1. Nonclinical Pharmacology................................ ..........................................24
2.2.2. Nonclinical Pharmacokinetics and Metabolism ............. ............................25
2.2.3. Nonclinical Safety ...................................... ................................................25
2.2.4. Clinical Overview....................................... ................................................25
2.3. Benefit/Risk Assessment................................... ......................................................26
2.3.1. Risk Assessment ......................................... ................................................27
2.3.2. Benefit Assessment...................................... ...............................................28
2.3.3. Overall Benefit/Risk Conclusion......................... .......................................28
3. OBJECTIVES AND ENDPOINTS .................................... .................................................28
4. STUDY DESIGN................................................ ............................................................... ..28
4.1. Overall Design............................................ .............................................................28
4.2. Scientific Rationale for Study Design..................... ................................................30
4.2.1. Choice of Contraception/Barrier Requirements ............ .............................31
4.2.2. Collection of Retained Research Samples................. .................................31
4.3. Justification for Dose .................................... ..........................................................31
4.3.1. Encorafenib Dose Rationale .............................. .........................................31
4.3.2. Rabeprazole Drug Selection and Dose Rationale........... ............................32
4.4. End of Study Definition ................................... .......................................................32
5. STUDY POPULATION ............................................ ..........................................................32
5.1. Inclusion Criteria........................................ .............................................................32
5.2. Exclusion Criteria........................................ ............................................................33
5.3. Lifestyle Cons iderations................................... .......................................................35
5.3.1. Contraception........................................... ...................................................35
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 65.3.2. Meals and Dietary Restrictions.......................... .........................................36
5.3.3. Caffeine, Alcohol, and Tobacco .......................... .......................................36
5.3.4. Activity ................................................ .......................................................37
5.4. Screen Failures ........................................... .............................................................37
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY ................ .................37
6.1. Study Intervention(s) Administered ........................ ................................................37
6.1.1. Administration .......................................... ..................................................38
6.2. Preparation, Handling, Storage, and Accountability........ .......................................38
6.2.1. Preparation and Dispensing .............................. ..........................................39
6.3. Assignment to Study Intervention.......................... .................................................40
6.4. Blinding.................................................. ............................................................... ..40
6.5. Study Intervention Compliance............................. ..................................................40
6.6. Dose Modification......................................... ..........................................................40
6.7. Continued Access to Study Intervention After the End of th e Study......................40
6.8. Treatment of Overdose..................................... .......................................................40
6.9. Prior and Concomitant Therapy ............................. .................................................41
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL..................................... ......................................41
7.1. Discontinuation of Study Intervention ..................... ...............................................41
7.2. Participant Discontinuation/Withdrawal From the Study ..... ..................................41
7.2.1. Withdrawal of Consent................................... ............................................42
7.3. Lost to Follow-up ......................................... ...........................................................43
8. STUDY ASSESSMENTS AND PROCEDURES............................ ...................................43
8.1. Administrative and Baseline Procedures.................... .............................................43
8.2. Efficacy Assessments...................................... ........................................................44
8.3. Safety Assessments ........................................ .........................................................44
8.3.1. Physical Examinations................................... .............................................44
8.3.2. Vital Signs ............................................. .....................................................45
8.3.2.1. Blood Pressure and Pulse Rate......................... .........................45
8.3.3. Electrocardiograms...................................... ...............................................45
8.3.4. Clinical Safety Laboratory Test Assessments ............. ...............................46
8.3.5. COVID-19 Specific Assessments........................... ....................................47
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 78.4. Adverse Events, Serious Adverse Events, and Other Safety R eporting .................47
8.4.1. Time Period and Frequency for Collecting AE and SAE Info rmation.......47
8.4.1.1. Reporting SAEs to Pfizer Safety....................... ........................48
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF.......... .........48
8.4.2. Method of Detecting AEs and SAEs ........................ ..................................49
8.4.3. Follow-Up of AEs and SAEs................................ ......................................49
8.4.4. Regulatory Reporting Requirements for SAEs.............. .............................49
8.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure ....................... ..............................49
8.4.5.1. Exposure During Pregnancy............................. .........................50
8.4.5.2. Exposure During Breastfeeding ......................... .......................51
8.4.5.3. Occupational Exposure ................................. ............................52
8.4.6. Cardiovascular and Death Events......................... ......................................52
8.4.7. Disease -Related Events and/or Disease -Related Outcomes  Not 
Qualifying as AEs or SAEs...................................... ........................................52
8.4.8. Adverse Events of Special Interest...................... .......................................52
8.4.8.1. Lack of Efficacy...................................... ..................................52
8.4.9. Medical Device Deficiencies............................. .........................................52
8.4.10. Medication Errors ...................................... ...............................................52
8.5. Pharmacokinetics .......................................... ..........................................................53
8.5.1. Plasma for Analysis of Encorafenib ....................... ....................................53
8.5.2. Derivation of Pharmacokinetic Parameters ................ ................................54
8.6. Genetics.................................................. ............................................................... ..55
8.6.1. Specified Genetics ...................................... ................................................55
8.6.2. Retained Research Samples for Genetics .................. .................................55
8.7. Biomarkers ................................................ ..............................................................5 5
8.8. Immunogenicity Assessments ................................ .................................................55
8.9. Health Economics .......................................... .........................................................55
9. STATISTICAL C ONSIDERATIONS .................................. ..............................................55
9.1. Statistical Hypotheses .................................... .........................................................56
9.2. Analysis Sets ............................................. ..............................................................5 6
9.3. Statistical Analyses ....................................... ..........................................................56
9.3.1. Pharmacokinetic Analyses................................ ..........................................56
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 89.3.2. Other Safety Analyses ................................... .............................................57
9.3.3. Other Analyses............................................ ................................................58
9.3.3.1. Retained Research Sample Analyses ..................... ...................58
9.4. Interim Analyses .......................................... ...........................................................58
9.5. Sample Size Determination................................. ....................................................58
9.6. Data Monitoring Committee ................................. ..................................................59
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ................................................. .........................................................60
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Cons iderations ...............60
10.1.1. Regulatory and Ethical Considerations .................... ................................60
10.1.1.1. Reporting of Safety Issues and Serious Breaches of th e 
Protocol or ICH GCP............................................ .............................60
10.1.2. Informed Consent Process ................................ ........................................61
10.1.3. Data Protection ........................................ .................................................62
10.1.4. Committees Structure ................................... ............................................62
10.1.4.1. Data Monitoring Committee ............................. ......................62
10.1.5. Dissemination of Clinical Study Data ................... ...................................62
10.1.6. Data Quality Assurance ................................. ...........................................63
10.1.7. Source Documents....................................... .............................................65
10.1.8. Study and Site Start and Closure ....................... .......................................65
10.1.9. Publication Policy..................................... ................................................66
10.1.10. Sponsor’s Medically Qualified Individual.............. ................................67
10.2. Appendix 2: Clinical Laboratory Tests ...................... ...........................................68
10.3. Appendix 3: Adverse Events: Definitions and Procedures fo r Recording, 
Evaluating, Follow-Up, and Reporting ........................... ..........................................69
10.3.1. Definition of AE ....................................... ................................................69
10.3.2. Definition of an SAE ................................... .............................................70
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs Du ring 
the Active Collection Period................................... .........................................71
10.3.4. Reporting of SAEs...................................... ..............................................75
10.4. Appendix 4: Contraceptive and Barrier Guidance ............. ...................................76
10.4.1. Male Participant Reproductive Inclusion Criteria ....... .............................76
10.4.2. Female Participant Reproductive Inclusion Criteria..... ............................76
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 910.4.3. Woman of Childbearing Potential ........................ ....................................76
10.4.4. Contraception Methods.................................. ...........................................77
10.5. Appendix 5: Genetics ....................................... .....................................................80
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up  Assessments .......81
10.7. Appendix 7: Kidney Safety: Monitoring Guidelines ......... ...................................83
10.7.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury ..................................... .........................................83
10.7.2. Age-Specific Kidney Function Calculation Recommendation s...............83
10.7.2.1. Adults (18 Years and Above)—2021 CKD-EPI 
Equations10............................................................... .........................83
10.7.3. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities.................................................. .................................................83
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ... ................................84
10.9. Appendix 9: Abbreviations ................................ ...................................................86
11. REFERENCES ................................................. ............................................................... ..91
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 10LIST OF TABLES
Table 1. Periods 1, 2 and 3..................................... .................................................18
Table 2. Period 4............................................... ......................................................21
Table 3. Pharmacokinetic Assessments............................ ......................................22
Table 4. Summary of the Two New Tablet Formulations .............. ........................23
Table 5. Trial Design ............................................ ..................................................29
Table 6. Summary of Encorafenib Formulations..................... ...............................38
Table 7. Definitions of PK Parameters ............................ .......................................54
Table 8. Confidence Interval Estimation of PK Endpoints for Bioa vailability......58
Table 9. Confidence Interval Estimation of PK Endpoints for PPI Effect .............59
Table 10. Protocol-Required Safety Laboratory Assessments ....... ..........................68
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 111. PROTOCOL SUMMARY 
1.1. Synopsis Protocol Title: A Phase 1, Randomized, Open-Label Study in Healthy Participants  to 
Estimate the Bioavailability of two new Encorafenib Formulation s Relative to the Current 
Formulation and to Evaluate the Effect of a Proton-Pump Inhibit or on Encorafenib Plasma 
Pharmacokinetics
Brief Title: A Phase 1 Relative Bioavailability Study Evaluating two new Encor afenib
Formulations
Regulatory Agency Identification Number(s):
US IND Number: 111003
EudraCT Number: N/A
ClinicalTrials.gov ID:  Not Available
Pediatric Investigational Plan Number: N/A
Protocol Number: C4221024
Phase: 1
Rationale
In order to decrease the size of the current formulated encoraf enib capsule and improve the 
physical stability, 2 new encorafenib tablet formulations have b een developed. This study is 
intended to select the optimal tablet formulation for commercia lization based on the 
pharmacokinetics. In addition, the present dissolution data does not provide enough 
confidence to exclude the achlorhydric population (PPI effect) from the rBA study. Because 
of this difference, a preliminary assessment of the effect of a proton-pump inhibitor on the 
pharmacokinetics of the 2 encorafenib tablet formulations will also  be conducted to assist in 
the formulation selection.
Objectives and Endpoints
Objectives Endpoints
Primary: Primary: 
•To estimate the relative BA of 2 new encorafenib 
75-mg tablet formulations  to the commercially available encorafenib formulated capsule (CAP) administered under fasted conditions to adult healthy participants.•Plasma AUC
inf, AUC lastand C maxfor encorafenib 
(alone and with rabeprazole).
Secondary: Secondary: 
•To assess the safety and tolerability of the 3 
formulations (  and CAP) 
encorafenib 75 -mg, when given alone and in •Overall safety profile as characterized by 
laboratory tests, vital signs, ECGs, and adverse events.
PPDCCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 12Objectives Endpoints
combination with rabeprazole in adult healthy 
participants.
•To estimate the effect of rabeprazole on the PK 
of .•Other plasma PK parameters for encorafenib 
(alone and with rabeprazole): T max, t1/2, CL/F, and 
Vz/F, if possible. 
Overall Design
This study will be an open-label, randomized, 4-period, 6-seque nce study in adult healthy 
participants.
Number of ParticipantsA sufficient number of participants will be screened to ensure that at least 18 participants are 
enrolled in the study. 
Study Population:Key inclusion and exclusion criteria are listed below:Inclusion Criteria Participants must meet the following inclusion criteria to be el igible for enrollment into the 
study:
1. Participants must be male or female of non-childbearing poten tial of 18 years of age 
or older, inclusive, at the time of signing the ICD.
2. Male and female participants who are overtly healthy as deter mined by medical 
evaluation including medical hi story, physical examination, lab oratory tests, and 
cardiac monitoring.
3. Participants who are willing and able to comply with all sche duled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other stu dy procedures.
4. BMI of 17.5 to 30.5 kg/m
2; and a body weight >50 kg (110 lb). 
5. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions list ed in the ICD and in 
this protocol.
Exclusion Criteria Participants with any of the following characteristics/condition s will be excluded:
PPDCCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 131. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatr ic, neurological, or 
allergic disease. Evidence of any active and uncontrolled bacter ial or viral infection.
2. Any condition possibly affecting drug absorption (eg, gastrec tomy, cholecy stecto my). 
3. History of HIV infection, hepatitis B, or hepatitis C; positi ve testing for HIV, HBsAg, 
HBcAb or HCVAb. Hepatitis B vaccination is allowed.
4. Positive COVID-19 test at first admission.5. Other medical or psychiatric conditions, laboratory test abnor malities, other 
conditions or situations related to COVID-19 pandemic or, in th e investigator’s 
judgment, make the participant inappropriate for the study.
6. Use of prescription or non-prescription medications within 7 days prior to the first 
dose of encorafenib with the exception of moderate/potent CYP3A  inducers which 
are prohibited within 14 days plus 5 half-lives prior to the fi rst dose. 
7. History of known sensitivity to rabeprazole, substituted benz imidazoles or to any 
component of the rabeprazole formulation.
8. Previous administration with an investigational product (drug  or vaccine) within 30 
days. 
9. Known hypersensitivity to encorafenib or its excipients.10. A positive urine drug or cotinine test.11. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (dias tolic), following at 
least 5 minutes of supine rest. 
12. Baseline standard 12 lead ECG that demonstrates clinically r elevant abnormalities 
that may affect participant safety or interpretation of study r esults.
13. AST or ALT level ≥ 1.5 灤ULN.
14. Total bilirubin level ≥1.5 灤ULN.
15. Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m
2.
Study Arms and DurationFor Periods 1 through 3, participants will receive a single 75- mg encorafenib formulation 
during each period:  (Treatment A),  (Treatment B) and CAP (Tre atment C) 
formulations, all under fasted conditions. In order to provide the most flexibility, the 
participants may remain in the PCRU from the time of admission on Day -1 of Period 1 until 
PPDCCI CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 14discharge after the 48-hour PK collection in Period 4 based on the discretion of the 
investigator. There will be a minimum 5-day washout period betw een encorafenib doses in 
these periods. Serial PK samples will be collected prior to and  after administration of each 
encorafenib dose.
During Period 4, in order to evaluate the effect of rabeprazole  on the encorafenib PK for the 
2 new tablet formulations, participants will receive either a si ngle 75-mg dose of  
(Treatment D) or  (Treatment E) following 5 days of 20 mg QD rab eprazole. The 
rabeprazole dosing in Period 4 must begin only after the  48-ho ur PK sample in Period 3 has 
been collected. Serial PK samples will be collected prior to an d after encorafenib dosing. 
The total duration of the st udy will be approximately 90 days i ncluding screening. 
Participants will be confined to the PCRU for a maximum of 21 da ys. Participants who 
withdraw from the study may be replaced at the discretion of th e investigator and upon 
consultation with the sponsor.
Statistical MethodsRelative Bioavailability (Periods 1-3): Natural log transformed encorafenib AUC
inf(if data permit), AUC lastand C maxwill be 
analyzed using a mixed effect model with sequence, period and t reatment as fixed effects and 
participant within sequence as a random effect. Estimates of th e adjusted mean differences 
(Test-Reference) and corresponding 90% CIs will be obtained fro m the model. The adjusted 
mean differences and 90% CIs for the differences will be expone ntiated to provide estimates 
of the ratio of adjusted geometric means (Test/Reference) and 9 0% CIs for the ratios. 
Treatment C (encorafenib CAP) is the Reference Treatment while Treatments A and B 
(  and  tablet formulations) are the Test Treatments. This analy sis will include 
only data from Treatments A, B and C.
PPI effect (Period 4) : Natural log transformed encorafenib AUC
inf(if data permit), AUC lastand C maxwill be 
analyzed using ANOVA with treatment and sequence as a fixed eff ect and subject within 
sequence as a random effect. Estimates of the adjusted mean dif ferences (Test-Reference) 
and corresponding 90% CIs will be obtained from the model. The adjusted mean differences 
and 90% CIs for the differences will be exponentiated to provid e estimates of the ratio of 
adjusted geometric means (Test/Reference) and 90% CIs for the r atios. For the  tablet 
formulation, Treatment A ( tablet) is the Reference Treatment whi le Treatment D 
(  tablet administered with rabeprazole) is the Test Treatment ( this analysis will only 
include data from Treatments A and D). For the  tablet formulat ion, Treatment B 
 tablet) is the Reference Treatment while Treatment E (  tablet administered 
with rabeprazole) is the Test Treatment (this analysis will onl y include data from Treatments 
B and E).
PPDCCICCI
CCI CCI
CCI
CCI
CCI
CCICCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 15Ethical Considerations:
Potential Risk of Clinical Significance
Participants may experience some adverse events.Summary of Data/Rationale for Risk
Please see Section 2.2.4 for adverse event data of 
encorafenib in non-cancer participants. See the 
encorafenib IB for additional safety information.Mitigation Strategy
All participants will be confined in the clinical 
sites with close monitoring and only be discharged 
once all AEs are stabilized. If necessary, a 
participant will be transferred to a facility with an
appropriate level of care to achieve stabilization or 
until SAEs have resolved.
Study Intervention(s) Encorafenib, Rabeprazole
Most common risks associated with encorafenib
include headache, flushing/erythema, paresthesia, 
and feeling hot after a single dose.  The potential risks are based on AEs reported in 
previous clinical studies with encorafenib in 
healthy participants.AEs, vital signs, ECGs, and clinical laboratory 
test results will be monitored on an ongoing basis. 
Instructions for managing potential cases of drug-induced liver injury, should they occur, are provided in Appendix 6 .
Secondary skin neoplasms are known adverse 
effects of treatment with single-agent BRAF inhibitors including encorafenib.Risk of developing secondary skin neoplasms is 
evident in the oncology treatment setting involving BRAF inhibitors including encorafenib.This adverse event was not reported with any of the other 5 clinical studies already conducted with healthy participants. Additionally, this event has 
not been observed after a single encorafenib dose 
in any patient studies either.
Most common risks associated with rabeprazole
include pain, pharyngitis, infection, flatulence, and 
constipation.The potential risks are based on AEs reported in 
the USPI.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 16Other
Risk of COVID-19 contamination during study. During the ongoing pandemic, healthy 
participants could be infected with SARS-COV-2 virus through study participation. This could lead to increased health risk for the participants and others in the study.COVID-19 specific assessments will be conducted 
in this study according to Table 1 andTable 2 .
Encorafenib single doses to be administered in this study are n ot expected to provide any clinical benefit to healthy particip ants.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 171.2. Schema
Not applicable. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 181.3. Schedule of Activities
The SoA tables provide an overview of the protocol visits and pro cedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each proced ure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addi tion to those listed in the SoA tables, in order to conduct eval uations or 
assessments required to protect the well-being of the participa nt.
The scheduled activities are listed in Table 1 for Periods 1, 2 and 3 and in Table 2 for Period 4.
Table 1. Periods 1, 2 and 3
Visit Identifier
Abbreviations used 
in this table may be 
found in Section 
10.9.Screen Period 1 to Period 3 Early 
DiscontinuationNotes
Days Relative to 
Day 1Day -28 
to 
Day -2Day -1 Day 1 Day 2 Day 3 • All screening should be done ≤ 28 days before the first dose. 
• Study Day relative to start of study intervention (Day 1).
Hours After Dose 0 2 24 48 • Hour 0 = predose sample collection
Informed consent X • See Section 10.1.2 for additional information.
CRU confinement X →→ → → • Participants may be discharged on Day 3 after PK sample collecti on is 
completed at the discretion of the investigator.
Inclusion/exclusion criteriaXX • Reviewed at screening and admission.
Medical/medication 
historyXX • Medical history: illegal drug, alcohol and tobacco use. 
• Medication histor y: prescription, non- prescription or supplements.
Physical 
examination (full)XX • A full PE will only be performed either at screening or at admiss ion during 
Period 1.
Safety laboratorytestsXX X • Safety lab tests will be collected at screening, admission(s) an d discharge, and at 
the discretion of the investigator.
• See Section 10.2 for additional information on specific clinical laboratory test s.
Demography X
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 19Table 1. Periods 1, 2 and 3
Visit Identifier
Abbreviations used 
in this table may be 
found in Section 
10.9.Screen Period 1 to Period 3 Early 
DiscontinuationNotes
Days Relative to 
Day 1Day -28 
to 
Day -2Day -1 Day 1 Day 2 Day 3 • All screening should be done ≤ 28 days before the first dose. 
• Study Day relative to start of study intervention (Day 1).
Hours After Dose 0 2 24 48 • Hour 0 = predose sample collection
Height and body 
weightX • See Section 8.3.1
Contraception 
check XX X X • Contraception check on Day 3 if participant is discharged.
FSH X • See Section 10.4.3 for additional information.
Urine drug testing X X • Cotinine test included.
• If participants are confined to the PCRU between periods, Day -1 as sessments
not required.
• See Section 10.2 for additional information.
12-Lead ECG X X X X • See Section 8.3.3 for additional information.
• Triplicate ECGs will be conducted pre-dose on Day 1. All other ECG 
measurements will be single ECGs.  
Blood pressure and 
pulse rateXX X X • See Section 8.3.2 for additional information.
HIV, HBsAg, 
HBcAb, HCVAb X • See Section 10.2 for additional information.
COVID-19 
questionnaireXX • Per local PCRU procedures.
COVID-19 PCR
testingX • See Section 8.3.5 and Section 10.2 for additional information.
• Per local PCRU procedures.
COVID-19 check 
temperatureX • Per local PCRU procedures.
Encorafenib 
administrationX • See Section 6.1.1 for additional information.
Pharmacokinetic 
blood sampling for 
encorafenibX→→ → X • Refer to Table 3 and Section 8.5 for additional information.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 20Table 1. Periods 1, 2 and 3
Visit Identifier
Abbreviations used 
in this table may be 
found in Section 
10.9.Screen Period 1 to Period 3 Early 
DiscontinuationNotes
Days Relative to 
Day 1Day -28 
to 
Day -2Day -1 Day 1 Day 2 Day 3 • All screening should be done ≤ 28 days before the first dose. 
• Study Day relative to start of study intervention (Day 1).
Hours After Dose 0 2 24 48 • Hour 0 = predose sample collection
Retained Research 
Sample for 
Genetics (Prep D1) X
(Peri
od 1 
only
)• Prep D1 Retained Research Samples for Genetics: If not collected  on the 
designated collection day, collect at the next available time p oint when 
biospecimens are being collected in conjunction with a particip ant visit. See 
Section 8.6.2 .
Concomitant 
treatment(s)XX X →→ → X • See SeSection 6.9 for additional information.
Serious and 
nonserious AE 
monitoringXX X →→ → X • See Section 8.4.3 for follow-up AE and SAE assessments.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 21Table 2. Period 4
Visit Identifier
Abbreviations used 
in this table may be 
found in Section 
10.9.Period 4 F/U Early 
DiscontinuationNotes
Days Relative to 
Day 1Day -
5Day -4 
to Day 
-1Day 1 Day 
2Day 3 29-
35 
Days• Day relative to start of study intervention (Day 1).
• Follow-up may occur via telephone. Contact and must occur 29 to  35 days after 
administration of the final dose of study intervention
Hours After Dose 0 2 24 48 • Hour 0 = predose sample collection
CRU confinement X →→→→ X 
Safety laboratory
testsXX • See Section 10.2 for additional information on specific clinical laboratory test s.
Contraception 
check XX • See Section 10.4 for additional information.
12-Lead ECG X X X • See Section 8.3.3 for additional information.
• Triplicate ECGs will be conducted pre-dose on Day 1. All other ECG 
measurements will be single ECGs.  
Blood pressure and 
pulse rateXX X • See Section 8.3.2 for additional information.
Rabeprazole 
administrationXX • See Section 6.1.1 for additional information.
Encorafenib 
administrationX • See Section 6.1.1 for additional information.
Pharmacokinetic 
blood sampling for encorafenibX→→→ X • Refer to Table 3 and Section 8.5 for additional information.
CRU discharge X
Concomitant 
treatment(s)XXX →→→ XX • See Section 6.9 for additional information.
Serious and 
nonserious AE 
monitoringXXX →→→ XX • See Section 8.4.3 for follow-up AE and SAE assessments.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 22Table 3. Pharmacokinetic Assessments
Notes
Study Day12 3 Day relative to start of study 
intervention (Day 1).
Hours Before/After Dose 0 0.5 1 1.5 2 2.5 3 3.5 4 6 8 10 12 24 48Hour 0 = predose sample collection
Encorafenib administration X
Encorafenib PK blood sampling X X X X X X X X X X X X X X X
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 232. INTRODUCTION
Encorafenib is a kinase inhibitor indicated, in combination wit h binimetinib, for the treatment 
of patients with unresectable or metastatic melanoma with a BRA F V600E or V600K 
mutation, as detected by an FDA-approved test, or in combination  with cetuximab, for the 
treatment of patients with mCRC with a BRAF V600E mutation, as detected by an FDA-
approved test, after prior therapy.
2.1. Study Rationale 
Formulated drug product containing encorafenib is currently avai lable as a 75-mg size double 
zero capsule for commercial uses. At the approved dose for metast atic melanoma (450 mg
QD), patients are required to swallow 6 capsules each day within a  short period of time. The 
capsule burden and challenge for many patients to consistently ingest six double-zero 
capsules has been noted during clinical development and subsequ ently post-
commercialization. Patients have often requested the option to open the capsules because 
they are too large to swallow. Additionally, there is an effort to improve the physical stability
of encorafenib for primary packaging flexibility. Therefore, the re is a need for a formulation
that is smaller in size with improved stability; this is the basi s for evaluation of the BA of the 
alternate formulation relative to the CAP for future commercial use . 
Alternative formulations have been developed as IR tablets, to deliv er the 75-mg dose in a 
10mm standard round tablet, improve physical stability, and are in tended to provide an 
alternative dosage form to be used for all patients, especially  those who have difficulty in 
swallowing the commercial capsules.
Two encorafenib tablet formulations are being evaluated in this cl inical study. Both novel 
formulations contain the same HME composition which contains enc orafenib within an
amorphous solid dispersion. The formulations differ in the extr agranular excipients chosen to 
compress the tablet cores. Specifically, the formulation design ated as contains only 
 as the extragranular diluent and the formulation designated as  
contains  as the extragranular diluents. These 2
tablet formulations are differentiated in terms of dissolution re lease profile and the clinical 
evaluation of both tablet core compositions will provide elucid ation of formulation design 
space which can be used to inform future commercial formulation  design strategies for 
encorafenib. For clarity, details regarding the 2 tablet formulati ons are provided in Table 4.
Table 4. Summary of the Two New Tablet Formulations
Name and Description Tablet Abbreviation Description
 Immediate-release tablet   
formulated with  as the single 
extragranular diluent
    Immediate-release tablet   
formulated with both  and 
 as extragranular diluents
PPDCCI
CCI
CCI CCI
CCI
CCI
CCICCICCICCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 24This study is intended to select the optimal tablet formulation for commercialization based on 
the PK. In addition, a preliminary assessment of the effect of a  PPI on the PK of the 2
encorafenib tablet formulations will also be conducted to assis t in the formulation selection.
2.2. Background 
Encorafenib is a novel oral small-molecule kinase inhibitor, wh ich suppresses the 
RAF/MEK/ERK pathway in tumor cells expressing the BRAF V600E muta tion. Similar to 
other selective small molecule RAF kinase inhibitors, encorafen ib inhibits COT and RAF-1 
(CRAF), BRAF, as well as BRAF V600E in cell-free assays. However,  this class of inhibitor 
does not inhibit RAF/MEK/ERK signaling in cells expressing wild -type BRAF. In the human 
melanoma cell line A375 (BRAF V600E), encorafenib potently inhib its phospho-MEK, 
phosphor-ERK and proliferation, resulting in cell cycle arrest and apoptosis. Given the high 
degree of selectivity against other kinases, encorafenib has no  antiproliferative activity in 
tumor cell lines that express wild-type BRAF and is highly sele ctive for BRAF V600E/D/K 
containing cell lines, with the greatest sensitivity observed i n BRAFmtmelanoma and CRC 
lineages. Encorafenib has been clinically evaluated in the onco logy setting as a single agent 
and in combination with other targeted agents, as well as in he althy subjects for 
bioavailability, human ADME, food effect, hepatic impairment an d DDIs.
2.2.1. Nonclinical PharmacologyEncorafenib is a highly selective ATP-competitive small-molecul e RAF kinase inhibitor 
which suppresses the RAF/MEK/ERK pathway in tumor cells express ing BRAFV600E. For 
example, the half-maximal response concentration (EC50) for sup pression of pMEK and 
pERK in A375 human melanoma cells are 2 nM and 3 nM, respective ly. Suppressi on of the 
RAF/MEK/ERK pathway causes cell cycle arrest which leads to inh ibition of cell 
proliferation with an EC50 = 4 nM. Similar to other selective s mall-molecule RAF kinase 
inhibitors, encorafenib inhibits CRAF, BRAF, as well as BRAF V60 0E in cell-free assays; 
however, this class of inhibitor does not inhibit RAF/MEK/ERK s ignaling in cells expressing 
wild-type BRAF. Given both the high degree of selectivity of en corafenib for the RAF 
kinases in biochemical assays (only 2/75 non-RAF kinases inhibi ted at concentrations 
<1 μM), and the failure of encorafenib to inhibit wild-type RAF kinases in cells, encorafenib 
has no antiproliferative activity in tumor cell lines that expr ess wild-type BRAF.
Encorafenib’s predominant circulating metabolite, LYH746 (also k nown as M42.5A), was 
assessed for its off-target activity on 56 G-protein-coupled re ceptors, transporters, ion 
channels, nuclear receptors and enzymes since this metabolite r epresented 15.5% of total 
radioactivity in plasma in the human ADME study. The results sh owed activities of > 50% 
inhibition at 10 μM were found on kinase insert domain receptor  (half-maximal inhibitory 
concentration [IC50] = 1.8 μM, n = 1) and PDE4D (IC50 = 4.2 μM,  n = 2), showing 
significantly less potency than encorafenib. LHY746 was also evalua ted in in vitro activity 
studies and confirmed to be inactive with respect to inhibiting  melanoma cell proliferation.
For more detailed information, refer to the current encorafenib IB.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 252.2.2. Nonclinical Pharmacokinetics and Metabolism
Encorafenib is a substrate of P-gp and is associated with a hig h apparent passive 
permeability. Binding to human plasma proteins was ~86%. Distri bution into rat tissues was 
rapid. There was no distribution to the CNS; brain and spinal c ord and no retention in the 
melanin-rich tissues. 
For all species investigated, m onohydroxylation, N -dealkylation , and subsequent 
glucuronidation represented the major metabolic pathways. Glucu ronidation, both direct and 
indirect, occurred more readily in humans than in other species.  Encorafenib is metabolized 
by CYP 3A4, CYP2C19, and CYP2D6. CYP3A4 was predicted to be the  major enzyme 
contributing to total oxidative clearance of encorafenib in hum an liver microsomes (~83.3%), 
followed by CYP2C19 and CYP2D6 (~16.0% and 0.71%, respectively) . 
In vitro experiments indicate that encorafenib is a relatively potent re versible inhibitor of 
uridine 5'-diphospho-glucuronosyltransferase-glucuronosyltransf erase (UGT) 1A1, CYP2B6, 
CYP2C9, and CYP3A4/5, and also a time-dependent inhibitor of CYP 3A4. Encorafenib 
induced CYP1A2, CYP2B6, CYP2C9, and CYP3A4 in human primary hepa tocytes. Finally, 
encorafenib was found to be a weak inhibitor of BCRP, and a pote nt inhibitor of renal 
transporters OCT 2, OAT 1, OAT3 and hepatic transporters OCT1, O ATP1B1 and 
OATP1B3. For more detailed information, refer to the current enc orafenib IB.
2.2.3. Nonclinical Safety
Preclinical safety pharmacology data do not indicate a clinical  risk for QTc prolongation, or 
adverse effects on the CNS or respiratory system for encorafenib  or its primary metabolite, 
LHY746. 
The GLP Ames and chromosomal aberration assays as well as a rat micronucleus study 
indicate that encorafenib is not genotoxic. 
Encorafenib showed a potential for phototoxicity in a screen 3T3  NRU in vitro assay. 
Additionally, encorafenib did not show a sensitizing potential in the murine LLNA TIER I 
assay, although revealed a weak irritating potential. However, it tested negative in the 
primary skin irritation assay in rabbits.
For more detailed information, refer to the current encorafenib  IB.
2.2.4. Clinical Overview
As of the data cutoff date of 11 May 2020, a total of 2117 heal thy subjects and patients have 
received at least 1 dose of encorafenib, either as a single age nt or in combination with other 
targeted agents. These patients constitute the encorafenib safe ty population, which includes 
97 healthy subjects, 7 subjects with hepatic impairment and 201 3 patients with advanced 
cancer (410 patients who received single-agent encorafenib and 1614 patients who received 
encorafenib combination therapy, with 11 patients who received both single-agent 
encorafenib and encorafenib + binimetinib combination therapy a nd 4 patients who received 
encorafenib + binimetinib combination therapy in 2 different st udies). Based on the 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 26experience from these studies, encorafenib has demonstrated an acceptable and manageable 
safety profile. 
Rabeprazole will be used in Period 4 of this study for assessment  of the potential effect of a 
PPI on the PK of the HME formulations ( and  Rabeprazole is a comm only 
used PPI able to reduce gastric acid. The approved dose for del ayed release rabeprazole (for 
gastroesophageal reflux disease) is 20-mg QD. 
The first generation encorafenib capsule  was previously studie d with rabeprazole 20-mg in a 
Phase 1, open-label, 2-arm, parallel-group, fixed-sequence study . The results show that co-
administration of 100-mg encorafenib with rabeprazole had no ov erall effect on the extent of 
exposure and peak exposure to encorafenib, when 100-mg encorafe nib was co-administered 
with multiple oral once-daily doses of 20-mg rabeprazole, relat ive to when 100-mg 
encorafenib was administered alone. The administration of a sin gle 100 mg oral dose of 
encorafenib in the presence of multiple oral doses of 20-mg rab eprazole was safe (as 
evidenced by the absence of Grade 3/severe, Grade 4/life-threat ening, and Grade 5/death as 
well as the absence of subject discontinuation deemed necessary  by the Investigator due to 
AEs). In Period 4 of this study, 20 mg rabeprazole QD will be admi nistered for 5 days to 
explore the potential effect of a PPI on PK of both new tablet formulations.
For detailed clinical information, refer to the current encoraf enib IB. For additional 
information regarding rabeprazole, please refer to the current rabeprazole USPI.
2.3. Benefit/Risk Assessment
Encorafenib is not expected to provide any clinical benefit to he althy participants. This study 
is designed primarily to generate safety, tolerability, and pha rmacokinetic data for further 
clinical development of new tablet formulation and to inform the critical formulation 
compositional design parameters for commercial formulation deve lopment for encorafenib.
More detailed information about the known and expected benefits  and risks and reasonably 
expected AEs of encorafenib may be found in the current encorafenib  IB which is the SRSD 
for this study.
Information about the known and expected benefits and risks and  reasonably expected AEs 
of rabeprazole may be found in the rabeprazole USPI.
PPDCCI CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 272.3.1. Risk Assessment
Potential Risk of Clinical Significance
Participants may experience some adverse events.Summary of Data/Rationale for Risk
Please see Section 2.2.4 for adverse event data of 
encorafenib in non-cancer participants. See the 
encorafenib IB for additional safety information.Mitigation Strategy
All participants will be confined in the clinical 
sites with close monitoring and only be discharged 
once all AEs are stabilized. If necessary, a 
participant will be transferred to a facility with an
appropriate level of care to achieve stabilization or 
until SAEs have resolved.
Study Intervention(s) Encorafenib, Rabeprazole
Most common risks associated with encorafenibinclude headache, flushing/erythema, paresthesia, and feeling hot after a single dose.  The potential risks are based on AEs reported in 
previous clinical studies with encorafenib in healthy participants.AEs, vital signs, ECGs, and clinical laboratory 
test results will be monitored on an ongoing basis. Instructions for managing potential cases of drug-
induced liver injury, should they occur, are 
provided in Appendix 6 .
Secondary skin neoplasms are known adverse 
effects of treatment with single-agent BRAF 
inhibitors including encorafenib.Risk of developing secondary skin neoplasms is 
evident in the oncology treatment setting 
involving BRAF inhibitors including encorafenib.   This adverse event was not reported with any of the other 5 clinical studies already conducted with healthy participants. Additionally, this event has not been observed after a single encorafenib dose in any patient studies either.
Most common risks associated with rabeprazoleinclude pain, pharyngitis, infection, flatulence, and constipation.The potential risks are based on AEs reported in 
the USPI.
Other
Risk of COVID-19 contamination during study. During the ongoing pandemic, healthy participants 
could be infected with SARS-COV-2 virus through study participation. This could lead to increased 
health risk for the participants and others in the 
study.COVID-19 specific assessments will be conducted 
in this study according to Table 1 andTable 2 .
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 282.3.2. Benefit Assessment
No clinical benefit is expected for participants enrolled in th is study, but the results from this 
study are intended to develop and eventually commercialize a new  encorafenib formulation 
to extend the use of encorafenib in patients who have trouble sw allowing the capsule 
formulation currently on the market.
2.3.3. Overall Benefit/Risk Conclusion
Encorafenib single doses to be administered in this study are no t expected to provide any 
clinical benefit to healthy participants. This study is designed  primarily to generate PK data 
for evaluation of a new encorafenib formulation. Single oral dos es of 50-mg and 100-mg 
encorafenib have been safely administered previously to approxima tely 90 healthy 
participants in 5 healthy participant clinical studies. 
More detailed information about the known and expected benefits , risks, and reasonably 
expected AEs of encorafenib may be found in the current encorafen ib IB, which is the SRSD 
for this study.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary: 
•To estimate the relative BA of 2 new 
encorafenib 75-mg tablet formulations (and  to the commercially available encorafenib formulated capsule (CAP) 
administered under fasted conditions to adult 
healthy participants.•Plasma AUC
inf, AUC lastand C maxfor encorafenib
(alone and with rabeprazole).
Secondary: Secondary: 
•To assess the safety and tolerability of the 3 
formulations (  and CAP) encorafenib 75-mg, when given alone and in 
combination with rabeprazole in adult healthy 
participants.
•To estimate the effect of rabeprazole on the PK 
of  and •Overall safety profile as characterized by 
laboratory tests, vital signs, ECGs, and adverse events.
•Other plasma PK parameters for encorafenib
(alone and with rabeprazole): T
max, t1/2, CL/F, and 
Vz/F, if possible.
4. STUDY DESIGN
4.1. Overall DesignThis study will be an open-label, randomized, 4-period, 6-sequenc e study in adult healthy 
participants.
Periods 1 through 3 will estimate the relative bioavailability o f the 2 new encorafenib tablet 
formulations ( and  compared to the commercially available CAP for mulation 
using a 75-mg encorafenib single dose administered under fasted c ondition. Period 4 will 
explore the potential effect of a PPI (rabeprazole) on the PK o f encorafenib administered as 
PPDCCICCI
CCI
CCI CCI
CCI CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 29the and tablet formulations. Participants will receive either the  o r
formulation with rabeprazole in Period 4.
Participants will be randomized into 1 of 6 treatment sequences as outlined in Table 5.
For Periods 1 through 3, participants will receive a single 75-mg encorafenib formulation
during each period: (Treatment A), (Treatment B) and CAP (Treatme nt C) 
formulations, all under fasted conditions. In order to provide t he most flexibility, the 
participants may remain in the PCRU from the time of admission on Day -1 of Period 1 until 
discharge after the 48-hour PK collection in Period 4 based on t he discretion of the 
investigator. There will be a minimum 5-day washout period betw een encorafenib doses in 
these periods. Serial PK samples will be collected prior to and  after administration of each 
encorafenib dose.
During Period 4, in order to evaluate the effect of rabeprazole o n the encorafenib PK for the 
2 new tablet formulations, participants will receive either a sing le 75-mg dose of 
(Treatment D) or (Treatment E) following 5 days of 20 mg QD rabe prazole. The 
rabeprazole dosing in Period 4 must begin only after the 48-hour PK s ample in Period 3 has 
been collected. Serial PK samples will be collected prior to and  after encorafenib dosing. 
Approximately 18 participants will be enrolled into the study. E ach participant will receive 4
single 75-mg doses of encorafenib during Periods 1 through 4, and  in addition, 20-mg 
rabeprazole QD for 5 days in Period 4. 
The total duration of the study will be approximately 90 days inc luding screening. 
Participants will be confined to the PCRU for a maximum of 21 da ys. Participants who 
withdraw from the study may be replaced at the discretion of th e investigator and upon 
consultation with the sponsor.
Table 5. Trial Design
Treatment 
SequencePeriod 
1Washout Period 2 Washout Period 3 Washout Period 4
1 (N=3) A
At least 5
day
washoutaB
At least 5
day
washoutaC
At least 5
day
washoutaD
2 (N=3) A C B E
3 (N=3) B C A D
4 (N=3) B A C E
5 (N=3) C A B D
6 (N=3) C B A E
a.between successive encorafenib doses
Treatments: 
•Treatment A (Test 1 for BA evaluation, Reference 1 for PPI effec t): A single 75 mg 
encorafenib dose as the formulation will be administered on the morning of Day 1 
after an overnight fast of at least 10 hours. 
PPDCCI CCI CCI
CCI
CCI CCI
CCICCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 30•Treatment B (Test 2 for BA evaluation, Reference 2 PPI effect): A single 75 mg 
encorafenib dose as the formulation will be administered on the m orning of Day 
1 after an overnight fast of at least 10 hours. 
•Treatment C (Reference for BA evaluation): A single 75 mg encoraf enib dose as CAP
formulation will be administered on the morning of Day 1 after an overnight fast of at 
least 10 hours.
•Treatment D (Test 1 for PPI evaluation): 20 mg rabeprazole will b e administered 
approximately 1 hour prior to dinner on Day -5 through Day -1. A  single 75 mg 
encorafenib dose as formulation will be administered on the morn ing of Day 1 
after an overnight fast of at least 10 hours.
•Treatment E (Test 2 for PPI evaluation): 20 mg rabeprazole will be  administered 
approximately 1 hour prior to dinner on Day -5 through Day -1. A  single 75 mg 
encorafenib dose as formulation will be administered on the morn ing of Day 1
after an overnight fast of at least 10 hours.
4.2. Scientific Rationale for Study DesignSingle doses of encorafenib up to 100-mg have been safely admini stered to about 90 healthy 
participants in 5 clinical studies ensuring little risk to healthy  adult participants in the current 
study ( Section 2.2 ).
Genetic Toxicity : The GLP Ames and chromosomal aberration assays as well as a r at 
micronucleus study indicate that encorafenib is not genotoxic.
Washout period: The mean elimination half-life after a single dose of encorafen ib is 
approximately 3.5 hours. Thus, a 18-hour washout period (~5 half-l ives) is considered 
adequate for the washout of the encorafenib from plasma. During the study, plasma 
concentrations should typically have dropped to BLQ before admin istration of the next dose
(ie, no residual concentrations from the prior period) to minimi ze the carryover from the 
previous treatment. Based on previous clinical experience with encorafenib, a 5-day washout 
period is considered sufficient for plasma encorafenib concentrat ions to return to BLQ after 
administration of a single dose. Therefore, in this study, a 5- day washout period has been 
selected between successive encorafenib doses for periods with P K collections.
Rationale for Inclusion of PPI Assessment: Encorafenib being a weak base would require 
inclusion of achlorhydric subjects to assess the effect of a PPI  on the PK, unless a non-
significant difference (≤15%) between the dissolution profiles of first generation capsules 
and second generation tablets is demonstrated in a medium with pH  3.0–6.8.
1,2,3Selection of 
the exact medium within this pH range has proven to be complex due to various factors.
Considering this, the present dissolution data does not provide  enough confidence to exclude 
the achlorhydric population (PPI effect) from the rBA study. Bec ause of this difference, both 
new tablet formulations will also be tested for clinically signi ficant pH dependent 
interactions.
Study Treatment Rationale for Rabeprazole: PPIs are a group of drugs that have strong 
inhibitory effects on acid secretion in the stomach through sup pression of the gastric proton 
pump (H, K-ATPase). PPIs exert their effect by increasing gastri c pH and are the very 
PPDCCI
CCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 31important treatment options for acid-related diseases. All PPIs  showed inhibitory effect on 
CYP2C9, 2C19, and 3A4 to some extent. Among those PPIs, rabepra zole showed the lowest 
inhibitory potency compared to other PPIs.4,5In addition, rabeprazole is predominantly 
converted to a thioether metabolite by non-enzymatic reduction and metabolism by CYP 
enzymes is only the minor elimination pathway. Therefore, the i mpact of enzyme 
polymorphism (such as CYP2C19) would be the lowest for rabepraz ole among all PPIs.6,7
Meta-analysis of multiple studies shows that rabeprazole has re latively high antisecretory 
potency among PPIs tested.6Since acid control by PPIs is a sustained effect, PPIs are 
commonly given daily despite the short elimination half-life (a bout 2 hours or less).7Since 
encorafenib is partially metabolized by CYP2C19 there is a pote ntial that rabeprazole may 
increase encorafenib plasma concentrations due to its CYP2C19 in hibitory effect, to 
minimize potential drug interaction between rabeprazole and enc orafenib, in this study, 
rabeprazole as 20-mg will be administered in the evening from D ay -1 to Day -5, and 75-mg 
encorafenib will be administered in the morning on Day 1 for the evaluation of any potential 
effect of PPI on the PK of encorafenib. With the short half-lif e of rabeprazole, there will be 
minimal systemic exposure of rabeprazole at the time of rabepra zole administration in the 
current design.
4.2.1. Choice of Contraception/Barrier Requirements
Nonclinical studies suggest risk for severe manifestations of d evelopmental toxicity at 
relevant clinical exposures for encorafenib. Therefore, the use of a highly effective method of 
contraception is required for male participants and their femal e partners of childbearing 
potential (see Appendix 4 ). Only female participants on non-childbearing status will be 
enrolled.
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for furt her analyses which may, for 
example, provide greater understanding of the study interventio n.
4.3. Justification for Dose
4.3.1. Encorafenib Dose RationaleThe approved dose of encorafenib for the treatment of metastati c melanoma is 450-mg QD
(administered as six 75-mg capsules, in combination with binime tinib) and 300-mg QD
(administered as four 75-mg capsules, in combination with cetux imab) for mCRC. In clinical 
study CLGX818X2101, the MTD for encorafenib was determined to be 450-mg QD and 
encorafenib has demonstrated dose proportional PK from 50 to 700- mg following single-
dose administration in patients. Single 50-mg and 100-mg doses of encorafenib have been 
administered to approximately 90 adult healthy participants in 5  clinical studies and were 
well-tolerated and without any reported SAEs.
Based on the safety data of encorafenib and prior clinical exper ience as described above, a 
single 75-mg dose, with a 5 day washout between successive encor afenib doses, for 4 
periods, is expected to pose little risk to healthy adult partic ipants.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 324.3.2. Rabeprazole Drug Selection and Dose Rationale
Rabeprazole is primarily dosed at 20-mg QD for many of its most common indications 
(healing of erosive or ulcerative GERD, treatment of symptomati c GERD in adults). 
Additionally, the findings from 2 clinical studies8,9indicate that the rabeprazole dosing 
regimen utilized in this protocol will ensure an intragastric pH>4, thus allowing the 
evaluation of the maximum effect of gastric acid suppression on  encorafenib
pharmacokinetics.
4.4. End of Study Definition
The end of the study will be defined as the date of last schedul ed procedure shown in Table 2
for the last participant in the trial.
A participant will be considered to have completed the study if they have completed all
periods of the study, including the last scheduled procedure sho wn in Table 1 and Table 2 .
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate parti cipants are enrolled, including 
participants across diverse and representative racial and ethni c backgrounds. Use of a 
prescreening tool is utilized for study recruitment purposes, it will include collection of 
information that reflects the enrollment of a diverse participa nt population including, where 
permitted under local regulations, age, sex, and race, and ethn icity. The following eligibility 
criteria are designed to select participants for whom participa tion in the study is considered 
appropriate. All relevant medical and nonmedical conditions sho uld be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if a ll of the following criteria apply:
Age and Sex:
1. Participants must be male or female of non-childbearing poten tial (as defined in 
Appendix 4 , Section 10.4.3 ) of 18 years of age or older, inclusive, at the time of 
signing the ICD.
Refer to Appendix 4 for reproductive criteria for male Section 10.4.1 and female 
(Section 10.4.2 ) participants.
Type of Participant and Disease Characteristics:
2. Male and female participants who are overtly healthy as deter mined by medical 
evaluation including medical history, physical examination, labor atory tests, and 
cardiac monitoring.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 333. Participants who are willing and able to comply with all sche duled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other stu dy procedures.
Body Weight:
4. BMI of 17.5 to 30.5 kg/m2; and a body weight >50 kg (110 lb).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions list ed in the ICD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the followin g criteria apply:
Medical Conditions:
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular (including history o f prolonged QT 
syndrome), hepatic, psychiatric, neurological, or allergic dise ase (including drug 
allergies, but excluding untreated, asymptomatic, seasonal alle rgies at the time of 
dosing). Evidence of any active and uncontrolled bacterial or vi ral infection.
2. Any condition possibly affecting drug absorption (eg, gastrec tomy, cholecystectomy).
3. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
HBcAb or HCVAb. Hepatitis B vaccination is allowed.
4. Positive COVID-19 test at first admission.5. Other medical or psychiatric condition including recent (with in the past year) or 
active suicidal ideation/behavior or laboratory test abnormalit y or other conditions or 
situations related to COVID-19 pandemic that may increase the r isk of study 
participation or, in the investigator’s judgment, make the partic ipant inappropriate for 
the study.
Prior/Concomitant Therapy:
6. Use of prescription or non-prescription medications, includin g vitamins, herbal and 
dietary supplements, grapefruit/grapefruit containing products,  and Seville 
orange/Seville orange containing products within 7 days prior to the first dose of
encorafenib with the exception of moderate/potent CYP3A inducers  which are 
prohibited within 14 days plus 5 half-lives prior to the first dose of encorafenib. 
(Refer to Section 6.9 Prior and Concomitant Therapy for additional details).
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 347. History of known sensitivity to rabeprazole, substituted benz imidazoles or to any 
component of the rabeprazole formulation. (Refer to rabeprazole  USPI for additional 
warnings and precautions related to rabeprazole).
Prior/Concurrent Clinical Study Experience:
8. Previous administration with an investigational product (drug  or vaccine) within
30 days.
9. Known hypersensitivity to encorafenib or its excipients.
Diagnostic Assessments:
10. A positive urine drug or cotinine test.11. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastoli c), following at 
least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the aver age of the 3 BP 
values should be used to determine the participant’s eligibilit y.
12. Baseline standard 12-lead ECG that demonstrates clinically releva nt abnormalities 
that may affect participant safety or interpretation of study res ults (eg, QTcF >450 ms
(or a history of prolonged QT syndrome), complete LBBB, signs of  an acute or 
indeterminate- age myocardial infarction, ST-T interval changes s uggestive of 
myocardial ischemia, second- or third- degree AV block, or serious bradyarrhythmias 
or tachyarrhythmias). If the uncorrected QT interval is >450 ms, t his interval should 
be rate-corrected using the Fridericia method only and the resu lting QTcF should be 
used for decision making and reporting. If QTcF exceeds 450 ms and o r QRS exceeds 
120 ms, the ECG should be repeated twice and the average of the 3 QTcF and/or QRS 
values used to determine the participant’s eligibility. Computer -interpreted ECGs 
should be overread by a physician experienced in reading ECGs b efore excluding a 
participant.
13. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening, as assessed by the study-specific laboratory and con firmed by a single 
repeat test, if deemed necessary: 
•AST orALT level ≥1.5 × ULN;
•Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert’s 
syndrome may have direct bilirubin measured and would be eligib le for this study 
provided the direct bilirubin level is ≤ ULN.
•Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2(See for
Section 10.7.2 calculation method).
Other Exclusion Criteria:
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 3514. Male participants who are unwilling or unable to comply with  the contraception 
requirement listed in Section 10.4.1 .
15. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is define d as a pattern of 
5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit = 8 ounce s (240 mL) beer, 
1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
16. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or 
more within 60 days prior to dosing.
17. History of sensitivity to heparin or heparin-induced thrombo cytopenia.
18. Participants who currently smoke or use other nicotine produc ts (e.g. chewing 
tobacco, E-cigarettes).
19. Unwilling or unable to comply with the criteria in the Secti on 5.3 Lifestyle 
Considerations section of this protocol.
20. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by the investigator, a nd sponsor and sponsor 
delegate employees directly involved in the conduct of the stud y and their family 
members.
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Contraception 
The investigator or their designee, in consultation with the pa rticipant, will confirm that male 
participants are utilizing an appropriate method of contraceptio n for the individual participant 
and their partner(s) from the permitted list of contraception m ethods (see Appendix 4 , 
Section 10.4.4 ) and will confirm that the participant has been instructed in its consistent and 
correct use. It must be confirmed that female participants meet  the criteria for non-
childbearing potential. At time points indicated in SoA tables ( Table 1 and Table 2 ), the 
investigator or designee will inform the participant of the nee d to use highly effective
contraception consistently and correctly and document the conve rsation and the participant’s 
affirmation in the participant’s chart. Participants need to af firm their consistent and correct 
use of at least 1 of the selected methods of contraception, con sidering that their risk for 
pregnancy may have changed since the last visit. 
In addition, the investigator or designee will instruct the par ticipant to call immediately if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol-specified method, including if the participa nt will no longer use abstinence 
as the selected contraception method, or if pregnancy is known o r suspected in the participant 
or partner.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 365.3.2. Meals and Dietary Restrictions
•Participants must abstain from all food and drink (except water ) at least 4 hours prior 
to any safety laboratory evaluations and 10 hours prior to the c ollection of the predose 
PK sample on Day 1 of each period. Participants must also abstain  from all food and 
drink (except water) at least 4 hours post encorafenib dose on D ay 1 of each period.
•Breakfast will not be provided on Day 1 of each treatment perio d.
•Water will be permitted until 1 hour prior to encorafenib administ ration on Day 1 in 
each period. There will be no water restrictions for rabeprazole  dosing. Water may be 
consumed without restriction beginning 1 hour after dosing on Day  1 of each period. 
Noncaffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices—see 
below) may be consumed with meals and the evening snack.
•Lunch will be provided approximately 4 to 5 hours after encorafe nib dosing on Day 1 
of all periods
•Dinner will be provided approximately 9 to 10 hours after encoraf enib dosing on Day 
1 of all periods.
•An evening snack may be permitted.
•Participants will refrain from consuming red wine, grapefruit, o r grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from  7 days prior to the first 
dose of encorafenib until collection of the final PK blood sampl e on the study.  
•While participants are confined, their total daily nutritional c omposition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein. The daily  caloric intake 
per participant should not exceed approximately 3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
•Participants will abstain from caffeine-containing products for  24 hours prior to the 
start of encorafenib dosing on Day 1 until collection of the fi nal PK sample of each 
treatment period.  
•Participants will abstain from alcohol for 24 hours prior (or as  specified above for red 
wine) to admission to the CRU and continue abstaining from alco hol until collection 
of the final PK sample of each study period. Participants may u ndergo an alcohol 
breath test or blood alcohol test at any time at the discretion o f the investigator.
•Participants who currently smoke will not be enrolled in this s tudy.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 375.3.4. Activity
•Participants will abstain from strenuous exercise (eg, heavy li fting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each bloo d collection for clinical 
laboratory tests. Walking at a normal pace will be permitted. 
•In order to standardize the conditions on PK sampling days, part icipants will be 
required to refrain from lying down (except when required for B P, pulse rate, and 
ECG measurements), eating, and drinking beverages other than wa ter during the first 
4 hours after encorafenib dosing on Day 1 of each treatment period
5.4. Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in t his study (ie, screen failures) 
may be rescreened. Rescreened participants should be assigned t he same participant number 
as for the initial screening.
Additionally during screening:
•For eligibility purposes, vital signs, laboratory tests, or ECG  results may be repeated 
if an abnormal result is observed at the initial reading;
•In the event that the participation of a participant in the stu dy is delayed and any 
required screening procedures will be outside of the allowed scr eening window (28 
days), these screening procedures can be repeated;
•Participants who are not eligible based on a reversible medical  condition or 
mild/acute/intercurrent illness may be re-evaluated after furth er testing/examination 
or re-screened after the condition has resolved.
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study interventions are all prespecified investigational and no ninvestigational medicinal 
products, medical devices, and other interventions (eg, surgica l and behavioral) intended to 
be administered to the study participants during the study cond uct.
For the purposes of this protocol, the term investigational pro duct may be used 
synonymously with study intervention.
6.1. Study Intervention(s) Administered
Study interventions administered in this study will be encorafeni b and rabeprazole.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 38Table 6. Summary of Encorafenib Formulations
Treatment 
ReferencesaProtocol 
C4221024 
AbbreviationRoute of 
AdministrationDMID Description
Treatment A
Treatment DOral  
 
Treatment B
Treatment EOral  
 
Treatment C CAP Oral Encorafenib 75 mg Size 00 
white/flesh hard gelatin 
capsule
a. Treatment descriptions outlined in Section 4.1 .
Encorafenib 75 mg tablets and capsules will be supplied to the CRU  in bulk along with 
individual dosing containers for unit dosing.
Delayed release 20 mg rabeprazole will be supplied by the CRU.6.1.1. Administration
Following an overnight fast of at least 10 hours, participants w ill receive encorafenib at 
approximately 0800 hours (plus or minus 2 hours) on Day 1 of each period. The investigator 
site personnel will administer encorafenib capsule/tablet during  each period with 
approximately 240 mL of ambient temperature water. Participants  will swallow the 
capsule/tablet whole, and will not manipulate or chew the capsul e/tablet prior to swallowing.
During Period 4, the investigator site personnel will administe r a 20 mg rabeprazole tablet
with approximately 240 mL of ambient temperature water without food approximately 1 hour 
prior to the dinner on Day -5 to Day -1. Participants will swallo w rabeprazole tablet whole 
and will not manipulate or chew the tablet prior to swallowing.
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for ECG measurem ents), eating, and 
drinking beverages other than water during the first 4 hours aft er encorafenib dosing.
6.2. Preparation, Handling, Storage, and Accountability
1. The investigator or designee must confirm that appropriate co nditions (eg, 
temperature) have been maintained during transit for all study interventions received 
and any discrepancies are reported and resolved before use of t he study intervention. 
PPDCCI
CCI
CCI
CCICCI
CCICCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 392. Only participants enrolled in the study may receive study int ervention and only 
authorized site staff may supply, prepare, and/or administer stu dy intervention.
3. All study interventions must be stored in a secure, environme ntally controlled, and 
monitored (manual or automated recording) area in accordance wi th the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonwork ing days must 
indicate the minimum and maximum temperatures since previously d ocumented upon 
return to business.
4. Any excursions from the study intervention label storage cond itions should be 
reported to Pfizer upon discovery along with actions taken. The  site should actively 
pursue options for returning the study intervention to the labe led storage conditions, 
as soon as possible. Once an excursion is identified, the study  intervention must be 
quarantined and not used until Pfizer provides permission to us e the study 
intervention. Specific details regarding the excursion definiti on and information to
report for each excursion will be provided to the site in the I P manual.
5. Any storage conditions stated in the SRSD will be superseded by the storage 
conditions stated on the label.
6. Study interventions should be stored in their original contain ers.
7. The investigator, institution, head of the medical institutio n (where applicable), or 
authorized site staff is responsible for study intervention acc ountability, 
reconciliation, and record maintenance (ie, receipt, reconcilia tion, and final 
disposition records), such as the IPAL or sponsor-approved equi valent. All study 
interventions will be accounted for using a study intervention ac countability 
form/record.
8. Further guidance and information for the final disposition of  unused study 
interventions are provided in the IP manual. All destruction must  be adequately 
documented. If destruction is authorized to take place at the i nvestigator site, the 
investigator must ensure that the materials are destroyed in co mpliance with 
applicable environmental regulations, institutional policy, and  any special instructions 
provided by Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery : as described in the IPM.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator si te activities performed to make 
the study intervention ready for administration or dispensing to  the participant by qualified 
staff. Dispensing is defined as the provision of study interven tion, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 40participant, in accordance with this protocol. Local health aut hority regulations or 
investigator site guidelines may use alternative terms for these  activities.
Encorafenib tablets and capsules will be prepared at the CRU in  the individual dosing 
containers by 2 operators, 1 of whom is an appropriately qualifi ed and experienced member 
of the study staff (eg, physician, nurse, physician’s assistant , nurse practitioner, pharmacy 
assistant/technician, or pharmacist). The tablets and capsules will be provided in unit dose 
containers and labeled in accordance with Pfizer regulations an d the clinical site’s labeling 
requirements. 
The handling of rabeprazole should be according to the product p ackage insert.
6.3. Assignment to Study Intervention
The investigator’s knowledge of the treatment should not influe nce the decision to enroll a 
particular participant or affect the order in which participants  are enrolled. The investigator 
will assign participant numbers to the participants as they are screened for the study. Pfizer 
will provide a randomization schedule to the investigator and, in accordance with the 
randomization numbers, the participant will receive the study tr eatment regimen assigned to 
the corresponding randomization number.
6.4. Blinding
This will be an open label study. 
6.5. Study Intervention Compliance
When participants are dosed at the site, they will receive stud y intervention directly from the 
investigator or designee, under medical supervision. The date a nd time of each dose 
administered in the clinic will be recorded in the source docum ents and recorded in the CRF. 
The dose of study intervention and study participant identifica tion will be confirmed at the 
time of dosing by a member of the study site staff other than t he person administering the 
study intervention. Study site personnel will examine each parti cipant’s mouth to ensure that 
the study intervention was ingested.
6.6. Dose Modification
No dose modifications, dosing interruptions, or dosing delays w ill be allowed in this healthy 
participant study.
6.7. Continued Access to Study Intervention After the End of the  Study
No study intervention will be provided to participants at the end  of their study participation.
6.8. Treatment of Overdose
For this study, any dose of encorafenib greater than 75 mg within  a 24-hour time period will 
be considered an overdose.
There is no specific treatment for an overdose
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 41In the event of an overdose, the investigator should:
1. Contact the study medical monitor within 24 hours.2.Closely monitor the participant for any AEs/SAEs and laboratory  test abnormalities 
as medically appropriate and at least until the next scheduled follow-up.
3. Document the quantity of the excess dose as well as the durat ion of the overdose in 
the CRF.
4. Overdose is reportable to Pfizer Safety only when associated with an SAE.
5. Obtain a blood sample for PK analysis within 2 days from the d ate of the last dose of 
study intervention if requested by the study medical monitor (d etermined on a 
case-by-case basis).
6.9. Prior and Concomitant Therapy
Use of prescription or nonprescription drugs and dietary and he rbal supplements are 
prohibited within 7 days prior to the first dose of encorafenib w ith the exception of 
moderate/potent CYP3A inducers which are prohibited within 14 da ys plus 5 half-lives prior 
to the first dose of encorafenib. Limited use of nonprescriptio n medications that are not 
believed to affect participant safety or the overall results of  the study may be permitted on a 
case-by-case basis following approval by the sponsor .
During the study, acetaminophen (up to 1 g per 24-hour period) and ibuprofen (up to 800 mg 
per 24 hour period) may be administered at the discretion of th e PI.
All concomitant treatments taken during the study must be recor ded with indication, daily 
dose, and start and stop dates of administration. All participa nts will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of either st udy intervention will be 
documented as a prior treatment. Treatments taken after the fir st dose of study intervention 
will be documented as concomitant treatments.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIf study intervention is permanently discontinued, the particip ant will not remain in the study 
for further evaluation. See the SoA tables for data to be collected at the time of 
discontinuation of study intervention.
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at their o wn request. Reasons for 
discontinuation from the study include the following:
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 42•Refused further follow-up;
•Lost to follow-up;
•Death;
•Study terminated by sponsor;
•At the discretion of the investigator for safety, behavioral, c ompliance, or 
administrative reasons.
At the time of discontinuing from the study, if possible, an ea rly discontinuation visit should 
be conducted. See the SoA tables for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations t hat need to be completed. 
The early discontinuation visit applies only to participants who  are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants shou ld be questioned regarding 
their reason for withdrawal. The participant will be permanently  discontinued from the study 
intervention and the study at that time.
If a participant withdraws from the study, they may request dest ruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the 
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1 ) 
for disclosure of future information, no further evaluations wi ll be performed and no 
additional data will be collected. The sponsor may retain and c ontinue to use any data 
collected before such withdrawal of consent.
When a participant withdraws from the study because of an AE or SAE, the AE or SAE must 
be recorded on the case report form (CRF) and reported on the C linical Trial (CT) SAE 
Report. 
Lack of completion of all or any of the withdrawal/early termin ation procedures will not be 
viewed as protocol deviations so long as the participant’s safe ty was preserved.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study interv ention will remain in the study 
and must continue to be followed for protocol-specified follow- up procedures. The only 
exception to this is when a participant specifically withdraws c onsent for any further contact 
with them or persons previously authorized by the participant to provide this information. 
Participants should notify the investigator in writing of the d ecision to withdraw consent 
from future follow-up, whenever possible. The withdrawal of con sent should be explained in 
detail in the medical records by the investigator, as to whethe r the withdrawal is only from 
further receipt of study intervention or also from study procedu res and/or posttreatment study 
follow-up, and entered on the appropriate CRF page. In the even t that vital status (whether 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 43the participant is alive or dead) is being measured, publicly av ailable information should be 
used to determine vital status only as appropriately directed i n accordance with local law.
7.3. Lost to Follow-up 
A participant will be considered lost to follow-up if the parti cipant repeatedly fails to return 
for scheduled visits and is unable to be contacted by the study  site.
The following actions must be taken if a participant fails to r eturn to the clinic for a required 
study visit:
•The site must attempt to contact the participant and reschedule  the missed visit as 
soon as possible. Counsel the participant on the importance of m aintaining the 
assigned visit schedule and ascertain whether the participant w ishes to and/or should 
continue in the study;
•Before a participant is deemed lost to follow-up, the investiga tor or designee must 
make every effort to regain contact with the participant (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’ s last known mailing 
address or local equivalent methods). These contact attempts sh ould be documented 
in the participant’s medical record;
•Should the participant continue to be unreachable, the particip ant will be considered 
to have withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative and Baseline ProceduresThe investigator (or an appropriate delegate at the investigato r site) must obtain a signed and 
dated ICD before performing any study-specific procedures.  
Study procedures and their timing are summarized in the SoA tables. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those spe cified in the SoA tables, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria. The investigator wil l maintain a screening log to 
record details of all participants screened and to confirm elig ibility or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administra tion of the study intervention
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected d elays (eg, delayed drug 
shipment), then participants do not require rescreening if the laboratory test results obtained 
prior to first dose administration meet eligibility criteria.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 44A participant who qualified for this protocol but did not enroll f rom an earlier cohort/group
may be used in a subsequent cohort/group without rescreening, prov ided laboratory test 
results obtained prior to the first dose administration meet el igibility criteria for this study. In 
addition, other clinical assessments or specimen collections, e g, retained research samples, 
may be used without repeat collection, as appropriate.
Every effort should be made to ensure that protocol -required t ests and procedures are 
completed as described. However, it is anticipated that from ti me to time there may be 
circumstances outside the control of the investigator that make  it unfeasible to perform the 
test. In these cases, the investigator must take all steps nece ssary to ensure the safety and 
well-being of the participant. When a protocol -required test c annot be performed, the 
investigator will document the reason for the missed test and a ny corrective and preventive 
actions that they have taken to ensure that required processes a re adhered to as soon as 
possible. The study team must be informed of these incidents in  a timely manner.
If an IV catheter is utilized for blood sample collections, ECGs  and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion o f the catheter.
For samples being collected and shipped, detailed collection, p rocessing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
The total blood sampling volume for individual participants in this study will be
approximately 230 mL. The actual collection times of blood sampl ing may change; the time 
of actual collection will be recorded. Additional blood samples  may be taken for safety 
assessments at times specified by Pfizer, provided the total vo lume taken during the study 
does not exceed 550 mL during any period of 56 consecutive days.
To prepare for study participation, participants will be instru cted on the information in the 
Lifestyle Considerations and Prior and Concomitant Therapy sections of the protocol.
8.2. Efficacy Assessments
Efficacy assessments will not be applicable to this study
8.3. Safety Assessments
Planned time points for all safety assessments are provided in the SoA tables. Unscheduled 
safety measurements may be obtained at any time during the study  to assess any perceived 
safety issues.
8.3.1. Physical Examinations
A full physical examination will include, at a minimum, head, ear s, eyes, nose, mouth, skin, 
heart and lung examinations, lymph nodes, and gastrointestinal,  musculoskeletal, and 
neurological systems. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 45Physical examinations may be conducted by a physician, trained p hysician’s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and body weight w ill also be measured and recorded as per  Table 1 . For measuring 
body weight, a scale with appropriate range and resolution is use d and must be placed on a 
stable, flat surface. Participants must remove shoes, bulky lay ers of clothing, and jackets so
that only light clothing remains. They must also remove the con tents of their pockets and 
remain still during measurement of weight. 
Physical examination findings collected during the study will b e considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active coll ection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to8.4.3 .
8.3.2. Vital Signs
8.3.2.1. Blood Pressure and Pulse RateSupine BP will be measured with the participant’s arm supported a t the level of the heart, and 
recorded to the nearest mmHg after approximately 5 minutes of res t. The same arm 
(preferably the dominant arm) will be used throughout the study . Participants should be 
instructed not to speak during measurements.
The same properly sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is ac ceptable; however, when 
done manually, pulse rate will be measured in the brachial/radia l artery for at least 
30 seconds. When the timing of these measurements coincides with  a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of t he blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of sa fety data.
Any untoward vital sign findings that are identified during the  active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1 to 8.4.3 .
8.3.3. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the HR and measures PR interval, QT inter val, QTcF, and QRS 
complex. Alternative lead placement methodology using torso lead s (eg, Mason-Likar) 
should not be used given the potential risk of discrepancies wit h ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be perf ormed after the participant
has rested quietly for at least 5 minutes in a supine position. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 46Triplicate 12-lead ECGs will be obtained approximately 2 to 4 min utes apart; the average of 
the triplicate ECG measurements collected before dose administr ation on Day 1 of each 
period will serve as each participant’s baseline QTcF value.
To ensure safety of the participants, a qualified individual at  the investigator site will make 
comparisons to baseline measurements (the last measurement prior  to encorafenib dose in the 
first period). Additional ECG monitoring will occur if a) a pos tdose QTcF is increased by 
≥60 ms from the baseline andis >450 ms; or b) an absolute QTcF value is ≥500 ms for any 
scheduled ECG. If either of these conditions occurs, then 2 addit ional ECGs will be collected 
approximately 2 to 4 minutes apart to confirm the original measur ement. If the QTcF values 
from these repeated ECGs remain above the threshold value, then  a single ECG must be 
repeated at least hourly until QTcF values from 2 successive ECGs  fall below the threshold 
value that triggered the repeat measurement.
If a) a postdose QTcF remains ≥60 ms from the baseline andis >450 ms; or b) an absolute 
QT value is ≥500 ms for any scheduled ECG for greater than 4 hours ( or sooner, at the 
discretion of the investigator); or c) QTcF value get progressivel y longer, the participant
should undergo continuous ECG monitoring. A cardiologist should  be consulted if QTcF
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).
In some cases, it may be appropriate to repeat abnormal ECGs to  rule out improper lead 
placement as contributing to the ECG abnormality. It is importa nt that leads be placed in the 
same positions each time in order to achieve precise ECG record ings. If a machine-read 
QTcF value is prolonged, as defined above, repeat measurements m ay not be necessary if a 
qualified medical provider’s interpretation determines that the  QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 8 .
8.3.4. Clinical Safety Laboratory Test Assessments
SeeAppendix 2 for the list of clinical safety laboratory tests to be performe d and the SoA for 
the timing and frequency. All protocol-required laboratory asses sments, as defined in
Appendix 2 , must be conducted in accordance with the laboratory manual an d the SoA. 
Unscheduled clinical laboratory measurements may be obtained at  any time during the study 
to assess any perceived safety issues.  
The investigator must review the laboratory report, document thi s review, and record any 
clinically significant changes occurring during the study in the  AE section of the CRF. 
Clinically significant abnormal laboratory test findings are th ose that are not associated with 
the underlying disease, unless judged by the investigator to be  more severe than expected for 
the participant’s condition.
All laboratory tests with values considered clinically signific ant and abnormal during 
participation in the study or within 28 calendar days after the last dose of study intervention 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 47should be repeated until the values return to normal or baselin e or are no longer considered 
clinically significant by the investigator or study medical mon itor.
If such values do not return to normal/baseline within a period  of time judged reasonable by 
the investigator, the etiology should be identified and the spo nsor notified.
See Appendix 6 for suggested actions and follow-up assessments in the event of  potential 
DILI.
SeeAppendix 7 for instructions for laboratory testing to monitor kidney funct ion and 
reporting laboratory test abnormalities.
8.3.5. COVID-19 Specific Assessments
Participants will be tested for SARS-COVID-19 infection by PCR testing prior to being 
admitted to the clinic for confinement (Day -1 of Period 1) and a subsequent COVID-19 test 
will be performed after 4 days (ie, upon completion of 4 × 24 h ours of CRU confinement), or 
if they develop COVID-19 like symptoms. 
8.4. Adverse Events, Serious Adverse Events, and Other Safety Rep orting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may arise from symptoms or other complaints reported to the  investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, o r the participant’s legally 
authorized representative), or they may arise from clinical fin dings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and any qualified designees are responsible fo r detecting, documenting, and 
recording events that meet the definition of an AE or SAE and r emain responsible to pursue 
and obtain adequate information both to determine the outcome a nd to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (seeSection 7.1 ). 
During the active collection period as described in Section 8.4 .1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by Pfizer Safety  to obtain specific follow-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Infor mation
The time period for actively eliciting and collecting AEs and S AEs (“active collection 
period”) for each participant begins from the time the participa nt provides informed consent, 
which is obtained before undergoing any study-related procedure and/or receiving study 
intervention), through and including a minimum of 28 calendar da ys after the last 
administration of the study intervention.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 48Follow-up by the inve stigator continues throughout the active c ollection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level accept able to the investigator.
When a clinically important AE remains ongoing at the end of th e active collection period, 
follow-up by the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection  period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when cons ent is withdrawn.
If a participant permanently discontinues or temporarily discont inues study intervention
because of an AE or SAE, the AE or SAE must be recorded on the C RF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to actively seek information on  AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has complete d the study, and they consider 
the event to be reasonably related to the study intervention, t he investigator must promptly 
report the SAE to Pfizer using the CT SAE Report Form.
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection  period as described in 
Section 8.4.1 ar ereported to Pfizer Safety on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours,  as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the spon sor within 
24 hours of its being available.
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during t he active collection period, 
which begins after obtaining informed consent as described in Section 8.4.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by the participant.
As part of ongoing safety reviews conducted by the sponsor, any  nonserious AE that is 
determined by the sponsor to be serious will be reported by the  sponsor as an SAE. To assist 
in the determination of case seriousness, further information m ay be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical
study.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 498.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of  AEs and SAEs and the 
procedures for completing and transmitting SAE reports are prov ided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and /or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferr ed method to inquire about 
AE occurrences.
8.4.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required  to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, th e event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up information will include a description of  the event in sufficient detail to 
allow for a complete medical assessment of the case and indepen dent determination of 
possible causality. Any information relevant to the event, such  as concomitant medications 
and illnesses, must be provided. In the case of a participant de ath, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer  Safety. 
Further information on follow-up procedures is provided in Appendix 3 .
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE  is essential so that legal 
obligations and ethical responsibilities toward the safety of p articipants and the safety of a 
study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local  regulatory authority and other 
regulatory agencies about the safety of a study intervention un der clinical investigation. The 
sponsor will comply with country-specific regulatory requiremen ts relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigat ors.
Investigator safety reports must be prepared for SUSARs accordin g to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives SUSARs or other specific safety inf ormation (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify the IRB/EC, if appropriate according to lo cal requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Brea stfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the  study as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 50exposure include healthcare providers, family members, and othe rs who may be exposed. An 
environmental exposure may include EDP, EDB, and occupational e xposure.
Any such exposures to the study intervention under study are repo rtable to Pfizer Safety 
within 24 hours of investigator awareness.
8.4.5.1. Exposure During Pregnancy
An EDP occurs if: 
•A female participant is found to be pregnant while receiving or  after discontinuing 
study intervention .
•A male participant who is receiving or has discontinued study i ntervention
inseminates a female partner. 
•A female nonparticipant is found to be pregnant while being expo sed or having been 
exposed to study intervention because of environmental exposure.  Below are 
examples of environmental EDP:  
•A female family member or healthcare provider reports that she is  pregnant after 
having been exposed to the study intervention by ingestion or sk in contact.
•A male family member or healthcare provider who has been expose d to the study 
intervention by ingestion or skin contact then exposes his fema le partner prior to 
or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hour s of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The init ial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 
•If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and  an EDP 
Supplemental Form, regardless of whether an SAE has occurred. De tails of the 
pregnancy will be collected after the start of study interventi on and until 7 days after 
the last dose
•If EDP occurs in the setting of environmental exposure, the inv estigator must report 
information to Pfizer Safety using the CT SAE Report Form and ED P Supplemental 
Form. Since the exposure information does not pertain to the pa rticipant enrolled in 
the study, the information is not recorded on a CRF; however, a  copy of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pre gnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will f ollow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer S afety of the outcome as a 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 51follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinicall y possible, the structural 
integrity of the terminated fetus should be assessed by gross v isual inspection (unless 
preprocedure test findings are conclusive for a congenital anom aly and the findings are 
reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome  of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abo rtion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live-born ba by, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigat or should follow the procedures 
for reporting SAEs. Additional information about pregnancy outc omes that are reported to 
Pfizer Safety as SAEs follows: 
•Spontaneous abortion including miscarriage and missed abortion sh ould be reported 
as an SAE;
•Neonatal deaths that occur within 1 month of birth should be rep orted, without regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related  or possibly related to 
exposure to the study intervention. 
Additional information regarding the EDP may be requested by th e sponsor. Further 
follow-up of birth outcomes will be handled on a case-by-case b asis (eg, follow-up on 
preterm infants to identify de velopmental delays). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Par tner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Infor mation Form to provide to his 
partner.
8.4.5.2. Exposure During Breastfeeding
An EDB occurs if: 
•A female participant is found to be breastfeeding while receivi ng or after 
discontinuing study intervention.
•A female nonparticipant is found to be breastfeeding while being  exposed or having 
been exposed to study intervention (ie, environmental exposure) . An example of 
environmental EDB is a female family member or healthcare provid er who reports 
that she is breastfeeding after having been exposed to the stud y intervention by
ingestion or skin contact.  
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 52The investigator must report EDB to Pfizer Safety within 24 hour s of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The inf ormation must be reported 
using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, 
the exposure information does not pertain to the participant en rolled in the study , so the 
information is not recorded on a CRF. However, a copy of the com pleted CT SAE Report 
Form is maintained in the investigator site file.
An EDB report is not created when a Pfizer drug specifically app roved for use in 
breastfeeding women (eg, vitamins) is administered in accordanc e with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB.
8.4.5.3. Occupational Exposure
The investigator must report any instance of occupational expos ure to Pfizer Safety within 24 
hours of the investigator’s awareness using the CT SAE Report F orm regardless of whether 
there is an associated SAE. Since the information about the occ upational exposure does not 
pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed CT SAE Report Form must be main tained in the 
investigator site file.
8.4.6. Cardiovascular and Death Events
Not Applicable.
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not Applicable.
8.4.8. Adverse Events of Special Interest
Not Applicable.
8.4.8.1. Lack of Efficacy
This section is not applicable because efficacy is not expected  in this study population.
8.4.9. Medical Device Deficiencies
Not Applicable.
8.4.10. Medication Errors
Medication errors may result from the administration or consump tion of the study 
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 53Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly if associated with an 
SAE
Medication errors include:
•Medication errors involving participant exposure to the study in tervention;
•Potential medication errors or uses outside of what is foreseen  in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE pa ge.
Whether or not the medication error is accompanied by an AE, as  determined by the 
investigator, the medication error is recorded on the medicatio n error page of the CRF and, if 
applicable, any associated AE(s), serious and nonserious, are re corded on the AE page of the 
CRF.
In the event of a medication dosing error, the sponsor should b e notified within 24 hours.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.5. Pharmacokinetics 
8.5.1. Plasma for Analysis of EncorafenibBlood samples of approximately 3 mL will be collected into approp riately labeled tubes 
containing dipotassium ethylenediaminetetraacetic acid (K
2EDTA) or tripotassium 
ethylenediaminetetraacetic acid (K 3EDTA) for measurement of plasma concentrations of 
encorafenib as specified in the SoA. Instructions for the collection and handling of biological 
samples will be provided in the laboratory manual or by the spons or. The actual date and 
time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will rem ain the same. All efforts 
will be made to obtain the samples at the exact nominal time re lative to dosing. Collection of 
samples up to and including 10 hours after dose administration tha t are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes o f a 60-minute sample) will 
not be captured as a protocol deviation, as long as the exact t ime of the collection is noted on 
the source document and the CRF. Collection of samples more than 1 0 hours after dose
administration that are obtained ≤1 hour away from the nominal tim e relative to dosing will 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 54not be captured as a protocol deviation, as long as the exact t ime of the collection is noted on 
the source document and the CRF.
Samples will be used to evaluate the PK of encorafenib.  
 
.
Genetic analyses will not be performed on these plasma samples.  Participant confidentiality 
will be maintained.
Samples collected for measurement of plasma concentrations of e ncorafenib will be analyzed 
using a validated analytical method in compliance with applicab le SOPs.
The PK samples must be processed and shipped as indicated in th e instructions provided to 
the investigator site to maintain sample integrity. Any deviatio ns from the PK sample 
handling procedure (eg, sample collection and processing steps,  interim storage or shipping 
conditions), including any actions taken, must be documented an d reported to the sponsor. 
On a case-by-case basis, the sponsor may make a determination a s to whether sample 
integrity has been compromised.
8.5.2. Derivation of Pharmacokinetic Parameters
PK parameters, as appropriate, will be derived from the encorafe nib concentration-time 
profiles as described in Table 7.
Table 7. Definitions of PK Parameters
Parameter Definition Method of Determination
AUC last Area under the plasma 
concentration time profile from time zero to the time of the last 
quantifiable concentration (C
last)Linear-log trapezoidal method.
AUC infaArea under the plasma 
concentration-time profile from time zero extrapolated to infinite timeAUC
last+ (C last/kel). 
where C lastis the predicted plasma 
concentration at the last quantifiable time point and kel is the elimination rate constant estimated from the log-linear regression analysis.
Cmax Maximum plasma concentration Observed directly from the data.
Tmax Time for C max Observed directly from the data as time of first occurrence.
t1/2aTerminal plasma elimination 
half-lifeLog e(2)/k el
Only those data points judged to 
describe the terminal log-linear decline will be used in the regression.
CL/FaApparent clearance after oral 
doseDose/AUC infafter oral dose.
PPDCCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 55Table 7. Definitions of PK Parameters
Parameter Definition Method of Determination
Vz/FaApparent volume of distribution 
after oral doseDose/(AUC inf*kel) after oral dose.
Tlast The time for C last Observed directly from the data
a. As data permits
Actual PK sampling times will be used in the derivation of PK p arameters whenever 
possible. In the case that actual PK sampling times are not ava ilable, nominal PK sampling 
time may be used in the derivation of PK parameters.
8.6. Genetics
8.6.1. Specified GeneticsSpecified genetic analyses are not evaluated in this study.
8.6.2. Retained Research Samples for Genetics
A 4-mL blood sample optimized for DNA isolation Prep D1 will be  collected according to 
the SoA tables, as local regulations and IRBs/ECs allow.
Retained Research Samples may be used for research related to th e study intervention(s). 
Genes and other analytes (eg, proteins, RNA, nondrug metabolites ) may be studied using the 
retained samples. 
SeeAppendix 5 for information regarding genetic research. Details on processes  for 
collection and shipment of these samples can be found in labora tory manual and supporting 
documentation.
8.7. Biomarkers
Biomarkers will not be evaluated in this study.
8.8. Immunogenicity Assessments
Immunogenicity assessments will not be included in this study.
8.9. Health Economics
Health economics/medical resource utilization and health econom ics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of th e data collected in this study 
is outlined here and further detailed in the Statistical Analys is Plan (SAP), which will be 
maintained by the sponsor. The SAP may modify what is outlined in the protocol where 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 56appropriate; however, any major modifications of the primary en dpoint definitions or their 
analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are define d:
Participant Analysis 
SetDescription
Enrolled “Enrolled” means a participant’s, or their legally autho rized 
representative’s, agreement to participate in a clinical study following completion of the informed consent process and screening. A participant will be considered enrolled if the informed consent is not withdrawn prior to participating in any  
study activity after screening. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by the protocol.
Safety analysis set All participants randomly assigned to a treat ment sequence and 
who take at least 1 dose of encorafenib. Participants will be analyzed according to the formulation they actually received.
PK Concentration Analysis SetThe PK concentration population is defined as all participants 
randomized and treated who have at least 1 encorafenib concentration in at least 1 period.
PK Parameter Analysis SetThe PK parameter analysis population is defined as all 
participants randomized and treated who have at least 1 of the encorafenib plasma PK parameters of primary interest in at least 1 treatment period.
9.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing , unused, and spurious data.
This section is a summary of the planned statistical analyses o f the primary and secondary 
endpoints.
9.3.1. Pharmacokinetic Analyses
Encorafenib PK parameters following a single dose administratio n will be derived from the 
encorafenib plasma concentration versus time profiles using non -compartmental methods as 
data permit. The PK parameters to be assessed in this study, th eir definition, and method of 
determination are outlined in Table 6. Encorafenib PK parameters  (AUC inf, AUC last, Cmax, 
Tmax, t1/2, CL/F, and V z/F) will be summarized descriptively by treatment. Individual
participant parameters for AUC inf, AUC last and Cmaxwill be plotted by treatment and overlaid 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 57with geometric mean. Similar presentations will also be made for  other PK parameters, if 
considered relevant. Encorafenib concentrations will be listed and summarized descriptively 
by PK sampling time and treatment. Summary profiles (means and medians) of concentration 
time data will be plotted by treatment on linear and semi log sc ale. Individual participant 
concentration time profiles will be also presented. For summary  statistics and summary plots
by sampling time, the nominal PK sampling time will be used, fo r individual participant plots 
by time, the actual PK sampling time will be used.
Relative Bioavailability (Periods 1-3): Natural log transformed encorafenib AUC
inf(if data permit), AUC lastand C maxwill be 
analyzed using a mixed effect model with sequence, period and t reatment as fixed effects and 
participant within sequence as a random effect. Estimates of th e adjusted mean differences 
(Test-Reference) and corresponding 90% CIs will be obtained fro m the model. The adjusted 
mean differences and 90% CIs for the differences will be expone ntiated to provide estimates 
of the ratio of adjusted geometric means (Test/Reference) and 9 0% CIs for the ratios. 
Treatment C (encorafenib CAP) is the Reference Treatment while T reatments A and B 
( and tablet formulations) are the Test Treatments. This analysis  will include 
only data from Treatments A, B and C.
PPI effect (Period 4) : Natural log transformed encorafenib AUC
inf(if data permit), AUC lastand C maxwill be 
analyzed using ANOVA with treatment and sequence as a fixed eff ect and subject within 
sequence as a random effect. Estimates of the adjusted mean dif ferences (Test-Reference) 
and corresponding 90% CIs will be obtained from the model. The a djusted mean differences 
and 90% CIs for the differences will be exponentiated to provid e estimates of the ratio of 
adjusted geometric means (Test/Reference) and 90% CIs for the r atios. For the tablet
formulation, Treatment A ( tablet) is the Reference Treatment wh ile Treatment D
( tablet administered with rabeprazole) is the Test Treatment (th is analysis will only 
include data from Treatments A and D). For the tablet formulation , Treatment B 
( tablet) is the Reference Treatment while Treatment E ( tablet ad ministered 
with rabeprazole) is the Test Treatment (this analysis will only  include data from Treatments 
B and E).
9.3.2. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BPs, pulse rates, and safety laboratory test data wil l be reviewed and 
summarized on an ongoing basis during the study to evaluate the  safety of par ticipants. Any 
clinical laboratory, ECG, BP, and pulse rate abnormalities of po tential clinical concern will 
be described. Safety data will be presented in tabular and/or g raphical format and 
summarized descriptively, where appropriate.
Medical history and physical examination information, as applic able, collected during the 
course of the study, will be considered source data and will not  be required to be reported, 
PPDCCI CCI
CCI
CCI
CCI
CCICCI
CCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 58unless otherwise noted. However, any untoward findings identifi ed on physical examinations
conducted during the active collection period will be captured as AEs, if those findings meet 
the definition of an AE. Data collected at screening that are u sed for inclusion/exclusion 
criteria, such as laboratory test data, ECGs, and vital signs, will be considered source data, 
and will not be required to be reported, unless otherwise noted . Demographic data collected 
at screening will be reported.
9.3.3. Other Analyses
9.3.3.1. Retained Research Sample AnalysesPharmacogenomic or biomarker data from Retained Research Sample s may be collected 
during or after the trial and retained for future analyses; the  results of such analyses are not 
planned to be included in the CSR.
9.4. Interim Analyses
No interim analysis will be conducted for this study. As this is  an open-label study, the
sponsor may conduct unblinded reviews of the data during the co urse of the study for the 
purpose of safety assessment, and/or supporting clinical developm ent.
9.5. Sample Size Determination
A sufficient number of participants will be screened to ensure that at least 18 participants are 
enrolled in the study.
The sample size is empirically selected and is not based on sta tistical power calculation.
For the comparison of the 2 new encorafenib tablet formulations  to the commercially 
available CAP, a sample size of 18 PK evaluable participants will  provide 90% CIs for the 
difference between treatments of ±0.1213 and ±0.1343 on the natu ral log scale for AUC
inf
and C max, respectively, with 80% coverage probability. Table 8 presents  the width of 90% CI 
for different estimated effects.
Table 8. Confidence Interval Estimation of PK Endpoints for Bioa vailability
ParameterEstimated Effect 
(100*Test/Reference) 90% CI CI Width
AUC inf 50%
70%80%90%
100%
110%
120%130%150%0.4429, 0.5645
0.6200, 0.79030.7086, 0.90320.7972, 1.01610.8857, 1.1290
0.9743, 1.2419
1.0629, 1.35481.1515, 1.46771.3286, 1.69350.1216
0.17030.19460.21890.2433
0.2676
0.29190.31620.3649
Cmax 50%70%80%
90%0.4371, 0.5719
0.6120, 0.80060.6994, 0.9150
0.7869, 1.02940.1347
0.18860.2156
0.2425
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 59Table 8. Confidence Interval Estimation of PK Endpoints for Bioa vailability
ParameterEstimated Effect 
(100*Test/Reference) 90% CI CI Width
100%
110%
120%130%150%0.8743, 1.1438
0.9617, 1.2582
1.0492, 1.37251.1366, 1.48691.3114, 1.71570.2695
0.2964
0.32340.35030.4042
For the potential effect of PPI, a sample size of 9 PK evaluabl e participants will provide 90% 
CIs for the difference between treatments of ±0.2017 and ±0.223 4 on the natural log scale for 
AUC infand C max, respectively, with 80% coverage probability. Table 9 presents  the width of 
90% CI for different estimated effects.
Table 9. Confidence Interval Estimation of PK Endpoints for PPI Effect
ParameterEstimated Effect 
(100*Test/Reference) 90% CI CI Width
AUC inf 50%70%
80%
90%
100%110%120%130%
150%0.4087, 0.6118
0.5721, 0.8565
0.6538, 0.9788
0.7356, 1.10120.8173, 1.22350.8990, 1.34590.9808, 1.46821.0625, 1.5906
1.2260, 1.83530.2031
0.2844
0.3250
0.36560.40620.44690.48750.5281
0.6093
Cmax 50%
70%80%90%
100%110%
120%
130%150%0.3999, 0.6251
0.5599, 0.87520.6399, 1.00020.7198, 1.12520.7998, 1.25030.8798, 1.3753
0.9598, 1.5003
1.0398, 1.62541.1997, 1.87540.2252
0.31530.36040.40540.45040.4955
0.5405
0.58560.6757
These calculations are based on estimates of within-participant  standard deviation of 0.196
and 0.217 encorafenib for log eAUC infand log eCmaxrespectively, based on the results from
crossover studies ARRAY-818-105 and ARRAY-162-105.
9.6. Data Monitoring Committee
This study will not use a data monitoring committee (DMC).
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 6010. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Consi derations
10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol an d with the following:
•Consensus ethical principles derived from international guideli nes, including the 
Declaration of Helsinki and CIOMS International Ethical Guideli nes;
•Applicable ICH GCP guidelines;
•Applicable laws and regulations, including applicable privacy l aws.
The protocol, protocol amendments, ICD, SRSD(s), and other rele vant documents 
(eg, advertisements) must be reviewed and approved by the sponso r, submitted to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC bef ore the study is initiated.
Any amendments to the protocol will require IRB/EC approval bef ore implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
Protocols and any substantial amendments to the protocol will r equire health authority 
approval prior to initiation except for changes necessary to el iminate an immediate hazard to 
study participants.
The investigator will be responsible for the following:
•Providing written summaries of the status of the study to the I RB/EC annually or 
more frequently in accordance with the requirements, policies, a nd procedures 
established by the IRB/EC;
•Notifying the IRB/EC of SAEs or other significant safety findin gs as required by 
IRB/EC procedures;
•Providing oversight of the conduct of the study at the site and  adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European  regulation 
536/2014 for clinical studies, European Medical Device Regulati on 2017/745 for 
clinical device research, and all other applicable local regula tions.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the  Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, cli nical hold) by an applicable 
regulatory authority in any area of the world, or if the invest igator is aware of any new 
information that might influence the evaluation of the benefits  and risks of the study 
intervention, Pfizer should be informed immediately.  
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 61In addition, the investigator will inform Pfizer immediately of  any urgent safety measures 
taken by the investigator to protect the study participants aga inst any immediate hazard, and 
of any serious breaches of this protocol or of the ICH GCP guid elines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or the investigator’s representative will expla in the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study. The participant should be given sufficient time and oppor tunity to ask questions and to 
decide whether or not to participate in the trial.
Participants must be informed that their participation is volun tary. Participants will be 
required to sign a statement of informed consent that meets the  requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy and data protection r equirements, where 
applicable, and the IRB/EC or study center.
The investigator must ensure that each participant is fully info rmed about the nature and 
objectives of the study, the sharing of data related to the stu dy, and possible risks associated 
with participation, including the risks associated with the pro cessing of the participant’s 
personal data. 
The participant must be informed that their personal study -rela ted data will be used by the 
sponsor in accordance with local data protection law. The level  of disclosure must also be 
explained to the participant.
The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appoin ted by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory a uthorities.
The investigator further must ensure that each study participan t is fully informed about their
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written inform ed consent was obtained 
before the participant was enrolled in the study and the date o n which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the IRB/EC-approved ICD(s) 
during their participation in the study as required per local re gulations.
A copy of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 6210.1.3. Data Protection
All parties will comply with all applicable laws, including laws  regarding the implementation 
of organizational and technical measures to ensure protection o f participant data.
Participants’ personal data will be stored at the study site in  encrypted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will impleme nt appropriate technical and 
organizational measures to ensure that the personal data can be  recovered in the event of 
disaster. In the event of a potential personal data breach, the  study site will be responsible for 
determining whether a personal data breach has in fact occurred  and, if so, providing breach 
notifications as required by law.
To protect the rights and freedoms of participants with regard t o the processing of personal 
data, participants will be assigned a single, participant -spec ific numerical code. Any 
participant records or data sets that are transferred to the spo nsor will contain the numerical 
code; participant names will not be transferred. All other iden tifiable data transferred to the 
sponsor will be identified by this single, participant -specifi c code. The study site will 
maintain a confidential list of participants who participated i n the study, linking each 
participant’s numerical code to their actual identity and medica l record ID. In case of data 
transfer, the sponsor will protect the confidentiality of parti cipants’ personal data consistent 
with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and st ore study-related data are 
secured by technical and organizational security measures desig ned to protect such data 
against accidental or unlawful loss, alteration, or unauthorize d disclosure or access.
The sponsor maintains standard operating procedures on how to r espond in the event of 
unauthorized access, use, or disclosure of sponsor information or systems.
10.1.4. Committees Structure
10.1.4.1. Data Monitoring Committee This study will not use an E-DMC.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical st udy results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.go v), the EudraCT/CTIS, and/or 
www.pfizer.com, and other public registries and websites in acc ordance with applicable local 
laws/regulations. In addition, Pfizer reports study results out side of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, study results are reported by Pfizer in an object ive, accurate, balanced, and 
complete manner and are reported regardless of the outcome of t he study or the country in 
which the study was conducted.
www.clinicaltrials.gov
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 63Pfizer posts clinical trial results on www.clinicaltrials.gov f or Pfizer-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or  efficacy of a product, 
regardless of the geographical location in which the study is c onducted. These results are 
submitted for posting in accordance with the format and timelin es set forth by US law.
EudraCT/CTIS
Pfizer posts clinical trial results on EudraCT/CTIS for Pfizer-s ponsored interventional studies 
in accordance with the format and timelines set forth by EU req uirements.
www.pfizer.com
Pfizer posts CSR synopses and plain-language study results summ aries on www.pfizer.com 
for Pfizer-sponsored interventional studies at the same time th e corresponding study results 
are posted to www.clinicaltrials.gov. CSR synopses will have pers onally identifiable 
information anonymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publi sh clinical documents included 
in marketing applications. Clinical documents include summary d ocuments and CSRs 
including the protocol and protocol amendments, sample CRFs, an d SAPs. Clinical 
documents will have personally identifiable information anonymi zed.
Data sharing
Pfizer provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of 
the disease, target, or compound class. Pfizer will make data f rom these trials available 
24 months after study completion. Participant -level data will b e anonymized in accordance 
with applicable privacy laws and regulations. CSRs will have pe rsonally identifiable 
information anonymized.
Data requests are considered from qualified researchers with th e appropriate competencies to 
perform the proposed analyses. Research teams must include a bi ostatistician. Data will not 
be provided to applicants with significant conflicts of interes t, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, labo ratory data). The investigator is 
responsible for verifying that data entries are accurate and co rrect by physically or 
electronically signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Compl etion Requirements 
document.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 64The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secu red in a locked room to 
prevent access by unauthorized third parties.
QTLs are predefined parameters that are monitored during the stud y. Important deviations 
from the QTLs and any remedial actions taken will be summarized  in the CSR.
The investigator must permit study-related monitoring, audits, IRB/EC review, and
regulatory agency inspections and provide direct access to sour ce data documents. This 
verification may also occur after study completion. It is impor tant that the investigator(s) and 
their relevant personnel are available during the monitoring vi sits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of  study-critical data items and 
processes (eg, risk-based initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk-based monitoring), me thods, responsibilities, and 
requirements, including handling of noncompliance issues and mo nitoring techniques 
(central, virtual, or on-site monitoring), are provided in the da ta management plan and IQMP
maintained and utilized by the sponsor or designee.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the  conduct of this study must 
be retained by the investigator for 15 years after study complet ion unless local regulations or 
institutional policies require a longer retention period. No re cords may be destroyed during 
the retention period without the written approval of the sponso r. No records may be 
transferred to another location or party without written notifi cation to the sponsor. The 
investigator must ensure that the records continue to be stored  securely for as l ong as they are 
maintained.
When participant data are to be deleted, the investigator will e nsure that all copies of such 
data are promptly and irrevocably deleted from all systems.
The investigator(s) will notify the sponsor or its agents immed iately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site  for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present duri ng the inspection. The 
investigator site and investigator will promptly resolve any di screpancies that are identified 
between the study data and the participant’s medical records. T he investigator will promptly 
provide copies of the inspection findings to the sponsor or its  agent. Before response 
submission to the regulatory authorities, the investigator will  provide the sponsor or its 
agents with an opportunity to review and comment on responses t o any such findings.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 6510.1.7. Source Documents
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected. Source documents are filed at th e investigator site.
Data reported on the CRF or entered in the eCRF that are from s ource documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or tr ansfer records, depending on 
the study. Also, current medical records must be available.
In this study, the CRF will serve as the source document. A doc ument must be available at 
the investigative site that identifies those data that will be recorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes source data and its origin can b e found in the Source 
Document Locator, which is maintained by the sponsor’s designee  (Pfizer CRU).
Description of the use of the computerized system is documented in the Data Management 
Plan, which is maintained by the sponsor’s designee (Pfizer CRU ).
The investigator must maintain accurate documentation (source d ata) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that d ata entered into the CRF 
by authorized site personnel are accurate, complete, and verifi able from source documents; 
that the safety and rights of participants are being protected;  and that the study is being 
conducted in accordance with the currently approved protocol an d any other study 
agreements, ICH GCP guidelines, and all applicable regulatory r equirements.
10.1.8. Study and Site Start and Closure
The study start date is the date on which the clinical study wi ll be open for recruitment of 
participants.
The first act of recruitment is the date of the first participa nt’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site  or terminate the study at any 
time for any reason at the sole discretion of the sponsor, inclu ding (but not limited to) 
regulatory authority decision, change in opinion of the IRB/EC,  or change in benefit-risk 
assessment. Study sites will be closed upon study completion. A study site is considered 
closed when all required documents and study supplies have been  collected and a study-site 
closure visit has been performed.
The investigator may initiate study -site closure at any time up on notification to the sponsor
if requested to do so by the responsible IRB/EC or if such term ination is required to protect 
the health of study participants.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 66Reasons for the early closure of a study site by the sponsor ma y include but are not limited 
to:
•Failure of the investigator to comply with the protocol, the re quirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, o r the ICH GCP 
guidelines;
•Inadequate recruitment of participants by the investigator;
•Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponso r shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and an y CRO(s) used in the study of 
the reason for termination or suspension, as specified by the a pplicable regulatory 
requirements. The investigator shall promptly inform the partic ipant and should assure 
appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study ag reement. If there is any conflict 
between the contract and this protocol, the contract will contro l as to termination rights.
10.1.9. Publication Policy
The results of this study may be published or presented at scie ntific meetings by the 
investigator after publication of the overall study results or 1 year after the end of the study 
(or study termination), whichever comes first. 
The investigator agrees to refer to the primary publication in any subsequent publications, 
such as secondary manuscripts, and submits all manuscripts or a bstracts to the sponsor 30 
days before submission. This allows the sponsor to protect prop rietary information and to 
provide comments, and the investigator will, on request, remove  any previously undisclosed 
confidential information before disclosure, except for any stud y- or Pfizer-intervention 
related information necessary for the appropriate scientific pr esentation or understanding of 
the study results. 
For all publications relating to the study, the investigator wi ll comply with recognized ethical 
standards concerning publications and authorship, including tho se established by the 
International Committee of Medical Journal Editors. 
The sponsor will comply with the requirements for publication o f the overall study results 
covering all investigator sites. In accordance with standard ed itorial and ethical practice, the 
sponsor will support publication of multicenter studies only in their entirety and not as 
individual site data. In this case, a coordinating investigator  will be designated by mutual 
agreement. 
Authorship of publications for the overall study results will b e determined by mutual 
agreement and in line with International Committee of Medical J ournal Editors authorship 
requirements. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 67If publication is addressed in the clinical study agreement, th e publication policy set out in 
this section will not apply.
10.1.10. Sponsor’s Medically Qualified Individual
The contact information for the sponsor’s MQI for the study is d ocumented in the study 
contact list located in the CTMS . 
To facilitate access to their investigator and the sponsor’s MQ I for study-related medical 
questions or problems from nonstudy healthcare professionals, pa rticipants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identif ication number, and (c) site 
emergency phone number active 24 hours/day, 7 days per week.
The ECC is intended to augment, not replace, the established co mmunication pathways 
between the participant and their investigator and site staff, and between the investigator and 
sponsor study team. The ECC is only to be used by healthcare pro fessionals not involved in 
the research study, as a means of reaching the investigator or site staff related to the care of a 
participant. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 6810.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times  defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of 
the method of analysis or the type of analyzer used by the clin ical laboratory, or as derived 
from calculated values. These additional tests would not requir e additional collection of 
blood. Unscheduled clinical laboratory measurements may be obta ined at any time during the 
study to assess any perceived safety issues.
Table 10. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
MCV MCH MCHCPlatelet countWBC count
Neutrophils (Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)Urea and creatinine
Glucose (fasting)
Calcium
SodiumPotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseUric acidAlbuminTotal proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitritesLeukocyte esteraseUrobilinogen 
Urine bilirubin
Laboratory:
Microscopy a•COVID-19 PCR testing
•Urine drug screeningc
•Urine cotinine
•eGFR (calculated using 
CKD-EPI equation)
At screening only:
•FSHb
•Hepatitis B surface 
antigen
•Hepatitis B core antibody
•Hepatitis C antibody
•Human 
immunodeficiency virus
a. Only if UTI is suspected and urine dipstick is positive for n itrites or leukocyte esterase or both.
b. For confirmation of postmenopausal status only.c. The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, 
and amphetamines (others are site and study specific).
The investigator must review the laboratory report, document th is review, and record any 
clinically relevant changes occurring during the study in the A E section of the CRF.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 6910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition
•An AE is any untoward medical occurrence in a patient or clinic al study 
participant, temporally associated with the use of study interve ntion, whether or 
not considered related to the study intervention.
•Note: An AE can therefore be any unfavorable and unintended sig n (including an 
abnormal laboratory finding), symptom, or disease (new or exace rbated) 
temporally associated with the use of study intervention.
Events Meeting the AE Definition
•Any abnormal laboratory test results (hematology, clinical chem istry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, consi dered clinically 
significant in the medical and scientific judgment of the inves tigator. Any 
abnormal laboratory test results that meet any of the condition s below must be 
recorded as an AE:
•Is associated with accompanying symptoms;
•Requires additional diagnostic testing or medical/surgical inte rvention;
•Leads to a change in study dosing (outside of any protocol-spec ified dose 
adjustments) or discontinuation from the study, significant add itional 
concomitant drug treatment, or other therapy.
•Exacerbation of a chronic or intermittent preexisting condition , including an 
increase in either frequency and/or intensity of the condition.
•New condition detected or diagnosed after study intervention ad ministration,
even though it may have been present before the start of the st udy.
•Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdo se of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with pos sible 
suicidal/self-harming intent. Such overdoses should be reported  regardless of 
sequelae.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 70Events NOT Meeting the AE Definition
•Any clinically significant abnormal laboratory findings or othe r abnormal safety 
assessments that are associated with the underlying disease, unl ess judged by the 
investigator to be more severe than expected for the participan t’s condition.
•The disease/disorder being studied or expected progression, sig ns, or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
•Medical or surgical procedure (eg, endoscopy, appendectomy): th e condition that 
leads to the procedure is the AE.
•Situations in which an untoward medical occurrence did not occu r (social and/or 
convenience admission to a hospital).
•Anticipated day-to-day fluctuations of preexisting disease(s) o r condition(s) 
present or detected at the start of the study that do not worse n.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at an y dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers  to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypothetically might have caused death if it were mor e severe.
c. Requires inpatient hospitalization or prolongation of existin g hospitalization
In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emerge ncy ward for 
observation and/or treatment that would not have been appropria te in the physician’s 
office or outpatient setting. Complications that occur during ho spitalization are AEs. 
If a complication prolongs hospitalization or fulfills any othe r serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious.
Hospitalization for elective treatment of a preexisting conditi on that did not worsen 
from baseline is not considered an AE.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 71d. Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’ s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relat ively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may i nterfere with or 
prevent everyday life functions but do not constitute a substan tial disruption.
e. Is a congenital anomaly/birth defect
f. Is a suspected transmission via a Pfizer product of an infect ious agent, 
pathogenic or non-pathogenic 
The event may be suspected from clinical symptoms or laboratory  findings 
indicating an infection in a participant exposed to a Pfizer pr oduct. The terms 
“suspected transmission” and “transmission” are considered syno nymous. These 
cases are considered unexpected and handled as serious expedite d cases by 
pharmacovigilance personnel. Such cases are also considered for  reporting as 
product defects, if appropriate.
g. Other situations:
•Medical or scientific judgment should be exercised by the inves tigator in deciding 
whether SAE reporting is appropriate in other situations, such a s significant 
medical events that may jeopardize the participant or may requi re medical or 
surgical intervention to prevent one of the other outcomes list ed in the above 
definition. These events should usually be considered serious.
•Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchos pasm, blood 
dyscrasias or convulsions that do not result in hospitalization , or development of 
drug dependency or drug abuse.
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs Durin g the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on  the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safety through out the active 
collection period. These requirements are delineated for 3 type s of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 72It should be noted that the CT SAE Report Form for reporting of  SAE information is not 
the same as the AE page of the CRF. When the same data are colle cted, the forms must 
be completed in a consistent manner. AEs should be recorded usi ng concise medical 
terminology and the same AE term should be used on both the CRF  and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeedingAll AEs/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an AE or SAE are not captured in the CRFAll instances of EDP are 
reported (whether or not there is an associated SAE)*
All instances of EDB are 
reported (whether or not there is an associated SAE)**
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB)None. Exposure to a study 
non-participant is not collected on the CRFThe exposure (whether or 
not there is an associated AE or SAE) must be reported***
*EDP (with or without an associated AE or SAE): any pregnancy inform ation is reported to 
Pfizer Safety using the CT SAE Report Form and EDP Supplemental  Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safe ty using the CT SAE Report 
Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form, which  would also include 
details of any SAE that might be associated with the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to Pfizer Safety using the CT SAE Report Form. 
•When an AE or SAE occurs, it is the responsibility of the invest igator to review 
all documentation (eg, hospital progress notes, laboratory repo rts, and diagnostic 
reports) related to the event.
•The investigator will then record all relevant AE or SAE informa tion in the CRF.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 73•It is notacceptable for the investigator to send photocopies of the part icipant’s 
medical records to Pfizer Safety in lieu of completion of the C T SAE Report 
Form/AE or SAE CRF page.
•There may be instances when copies of medical records for certa in cases are 
requested by Pfizer Safety. In this case, all participant identif iers, with the 
exception of the participant number, will be redacted on the co pies of the medical 
records before submission to Pfizer Safety.
•The investigator will attempt to establish a diagnosis of the ev ent based on signs, 
symptoms, and/or other clinical information. Whenever possible,  the diagnosis 
(not the individual signs/symptoms) will be documented as the A E or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories : 
•Mild: A type of AE that is usually transient and may require on ly minimal 
treatment or therapeutic intervention.  The event does not gene rally interfere with 
usual ADL.
•Moderate: A type of AE that is usually alleviated with addition al specific 
therapeutic intervention. The event interferes with usual ADL, causing 
discomfort, but poses no significant or permanent risk of harm t o the research 
participant.
•Severe: A type of AE that interrupts usual ADL, or significantl y affects clinical 
status, or may require intensive therapeutic intervention.
An event is defined as “serious” when it meets at least 1 of th e predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
•The investigator is obligated to assess the relationship betwee n study intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
•A “reasonable possibility” of a relationship conveys that there  are facts, 
evidence, and/or arguments to suggest a causal relationship, ra ther than a 
relationship cannot be ruled out.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 74•Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event  to study intervention 
administration, will be considered and investigated.
•The investigator will also consult the IB and/or product inform ation, for 
marketed products, in their assessment.
•For each AE or SAE, the investigator must document in the medical notes that 
they have reviewed the AE or SAE and have provided an assessment o f causality.
•There may be situations in which an SAE has occurred and the in vestigator has 
minimal information to include in the initial report to the spo nsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data  to the 
sponsor .
•The investigator may change their opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated ca usality 
assessment.
•The causality assessment is one of the criteria used when deter mining regulatory 
reporting requirements.
•If the investigator does not know whether or not the study inte rvention caused the 
event, then the event will be handled as “related to study inte rvention” for 
reporting purposes, as defined by the sponsor. In addition, if the investigator 
determines that an SAE is associated with study procedures, the  investigator 
must record this causal relationship in the source documents an d CRF, and report 
such an assessment in the dedicated section of the CT SAE Repor t Form and in 
accordance with the SAE reporting requirements.
Follow-Up of AEs and SAEs
•The investigator is obligated to perform or arrange for the con duct of 
supplemental measurements and/or evaluations, as medically indic ated or as 
requested by the sponsor, to elucidate the nature and/or causali ty of the AE or 
SAE as fully as possible. This may include additional laborator y tests or 
investigations, histopathological examinations, or consultation  with other 
healthcare providers.
•If a participant dies during participation in the study or duri ng a recognized 
follow-up period, the investigator will provide Pfizer Safety w ith a copy of any 
postmortem findings, including histopathology.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 75•New or updated information will be recorded in the originally s ubmitted 
documents.
•The investigator will submit any updated SAE data to the sponso r within 24 
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic DCT
•The primary mechanism for reporting an SAE to Pfizer Safety will  be the 
electronic DCT.
•If the electronic system is unavailable, then the site will use  the paper SAE DCT
(see next section) to report the event within 24 hours.
•The site will enter the SAE data into the electronic DCT (eg, eS AE or PSSA) or 
paper form (as applicable) as soon as the data become available.
•After the study is completed at a given site, the electronic DC T will be taken 
off-line to prevent the entry of new data or changes to existin g data.
•If a site receives a report of a new SAE from a study participa nt or receives 
updated data on a previously reported SAE after the electronic DCT has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety by telephone.
SAE Reporting to Pfizer Safety via the CT SAE Report Form
•Facsimile transmission of the CT SAE Report Form is the preferre d method to 
transmit this information to Pfizer Safety.
•In circumstances when the facsimile is not working, an alternat ive method should 
be used, eg, secured (Transport Layer Security) or password-pro tected email. If 
none of these methods can be used, notification by telephone is  acceptable with a 
copy of the CT SAE Report Form sent by overnight mail or courier service.
•Initial notification via telephone does not replace the need fo r the investigator to 
complete and sign the CT SAE Report Form pages within the desig nated 
reporting time frames.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 7610.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study intervention, which 
corresponds to the time needed to eliminate reproductive safety  risk of the study 
intervention(s): 
•Refrain from donating sperm.
PLUS either :
•Be abstinent from heterosexual intercourse as their preferred a nd usual lifestyle 
(abstinent on a long-term and persistent basis) and agree to re main abstinent. 
OR
•Must agree to use contraception/barrier as detailed below:
•Agree to use a male condom, and should also be advised of the b enefit for a 
female partner to use a highly effective method of contraceptio n (refer to the list 
of highly effective methods below in Section 10.4.4 ), as a condom may break or 
leak, when having sexual intercourse with a WOCBP who is not cu rrently 
pregnant.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and S ex;Section 5.1 ) and specify 
the reproductive requirements for including female participants . Refer to Section 10.4.4 for a 
complete list of contraceptive methods permitted in the study. 
A female participant is eligible to participate if she:is not pregnant or breastfeeding and at least 1 of the following  conditions applies:
•Is not pregnant or breastfeeding
•Is not a WOCBP (see definitions below in Section 10.4.3).
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman w ith an early undetected 
pregnancy.
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until beco ming postmenopausal 
unless permanently sterile (see below).
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 77If fertility is unclear (eg, amenorrhea in adolescents or athle tes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, addit ional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:
•Documented hysterectomy;
•Documented bilateral salpingectomy;
•Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cau se other than the above
(eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied 
to determining study entry.
Note: Documentation for any of the above categories can come fr om the site personnel’s 
review of the participant’s medical records, medical examinatio n, or medical history 
interview. The method of documentation should be recorded in th e participant’s medical 
record for the study.
2. Postmenopausal female.
•A postmenopausal state is defined as no menses for 12 months wit hout an 
alternative medical cause. In addition:
•A high FSH level in the postmenopausal range must be used to co nfirm a 
postmenopausal state in women under 60 years old and not using h ormonal 
contraception or HRT. 
•A female on HRT and whose menopausal status is in doubt will be  required to 
use one of the highly effective nonestrogen hormonal contracept ion methods 
if she wishes to continue her HRT during the study. Otherwise, she m ust 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment.
10.4.4. Contraception Methods
Contraceptive use by men or female partners of male participants should be consistent with 
local availability/regulations regarding the use of contracepti ve methods for those 
participating in clinical trials.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 78The following contraceptive methods are appropriate for this st udy:
Highly Effective Methods That Have Low User Dependency 
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.3. Intrauterine hormone-releasing system.4. Bilateral tubal occlusion.5. Vasectomized partner.
•Vasectomized partner is a highly effective contraceptive method  provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highly effective method of contraception 
should be used.  The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contr aception associated 
with inhibition of ovulation:
•Oral + barrier*
•Intravaginal + barrier*
•Transdermal + barrier*
7. Progestogen-only hormone contraception associated with inhibi tion of ovulation:
•Oral + barrier*
•Injectable + barrier*
8. Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire peri od of risk associated 
with the study intervention.  The reliability of sexual abstine nce needs to be evaluated 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 79in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.
* Acceptable barrier methods to be used concomitantly with opti ons 6 or 7 for the study 
include any of the following:
•Male or female condom with or without spermicide;
•Cervical cap, diaphragm, or sponge with spermicide;
•A combination of male condom with either cervical cap, diaphrag m, or sponge 
with spermicide (double-barrier methods).
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 8010.5. Appendix 5: Genetics
Use/Analysis of DNA
•Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. The refore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected  for DNA analysis.
•The scope of the genetic research may be narrow (eg, 1 or more candi date genes) or
broad (eg, the entire genome), as appropriate to the scientific que stion under 
investigation.
•The samples may be analyzed as part of a multistudy assessment of genetic factors 
involved in the response to encorafenib or study interventions o f this class to 
understand treatments for the disease(s) under study or the dis ease(s) themselves.
•The results of genetic analyses may be reported in the CSR or in  a separate study 
summary, or may be used for internal decision making without bei ng included in a 
study report.
•The sponsor will store the DNA samples in a secure storage spac e with adequate 
measures to protect confidentiality. 
•The samples will be retained as indicated:
•Retained samples will be stored indefinitely or for another per iod as per local 
requirements.   
•Participants may withdraw their consent for the storage and/or use of their Retained 
Research Samples at any time by making a request to the investi gator; in this case, any 
remaining material will be destroyed. Data already generated fr om the samples will be 
retained to protect the integrity of existing analyses.   
•Samples for genetic research will be labeled with a code. The k ey between the code 
and the participant’s personally identifying information (eg, na me, address) will be 
held securely at the study site.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 8110.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as d etermined by elevations in 
transaminases) are termed “tolerators,” while those who show tr ansient liver injury but adapt 
are termed “adaptors.” In some participants, transaminase eleva tions are a harbinger of a 
more serious potential outcome. These participants fail to adap t and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × U LN should be monitored 
more frequently to determine if they are “adaptors” or are “sus ceptible.”
In the majority of DILI cases, elevations in AST and/or ALT pre cede T bili elevations 
(>2 × ULN) by several days or weeks. The increase in T bili typica lly occurs while 
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T b ili values will be 
elevated within the same laboratory sample). In rare instances, by the time T bili elevations 
are detected, AST/ALT values might have decreased. This occurre nce is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR  ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medica l events, even before all 
other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditi ons. Participants who present 
with the following laboratory abnormalities should be evaluated  further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
•Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bil i value ≥2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value  <2 × ULN or not 
available.
•For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned  above, as needed, 
depending on which values are above the ULN at baseline:
•Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥2 times the baseline values AND ≥3 × ULN; or ≥8 × ULN (which ever is 
smaller).
•Preexisting values of T bili above the normal range: T bili level  increased from 
baseline value by an amount of  ≥1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).
Rises in AST/ALT and T bili separated by more than a few weeks s hould be assessed 
individually based on clinical judgment; any case where uncerta inty remains as to whether it 
represents a potential Hy’s law case should be reviewed with th e sponsor. 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 82The participant should return to the investigator site and be ev aluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal result s. This evaluation should 
include laboratory tests, detailed history, and physical assess ment. 
In addition to repeating measurements of AST and ALT and T bili f or suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consid eration should also be given 
to drawing a separate tube of clotted blood and an anticoagulat ed tube of blood for further 
testing, as needed, for further contemporaneous analyses at the  time of the recognized initial 
abnormalities to determine etiology. A detailed history, includ ing relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itsel f or as a coformulated 
product in prescription or over-the-counter medications), recre ational drug, or supplement 
(herbal) use and consumption, family history, sexual history, t ravel history, history of contact 
with a jaundiced person, surgery, blood transfusion, history of  liver or allergic disease, and 
potential occupational exposure to chemicals, should be collect ed. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laborat ory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DI LI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnor malities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 8310.7. Appendix 7: Kidney Safety: Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and D etection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseli ne and postbaseline serum 
creatinine (Scr measurement to estimate glomerular filtration r ate [Scr-based eGFR] or 
creatinine clearance [eCrCl]). Baseline and postbaseline serum Scys makes it feasible to 
distinguish AKI from other causes of Scr increase. If Scr incre ase is confirmed after baseline, 
then reflex measurement of Scys is indicated to estimate the co mbined Scr-Scys eGFR 
calculation (for adults only).
Regardless of whether kidney function monitoring tests are requ ired as a routine safety 
monitoring procedure in the study, if the investigator or spons or deems it necessary to further 
assess kidney safety and quantify kidney function, then these t est results should be managed 
and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
10.7.2.1. Adults (18 Years and Above)—2021 CKD-EPI Equations10
2021 CKD-
EPI            
Scr OnlyScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ō0.7 N/A eGFR = 143 × (Scr/0.7)-0.241  ×  (0.9938)Age
Female if > 0.7 N/A eGFR = 143 × (Scr/0.7)-1.200  ×  (0.9938)Age
Male if ō0.9 N/A eGFR = 142 × (Scr/0.9)-0.302  ×  (0.9938)Age
Male if > 0.9 N/A eGFR = 142 × (Scr/0.9)-1.200  ×  (0.9938)Age
2021 CKD-
EPI           
Scr-Scys 
CombinedScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ō0.7 if ō0.8 eGFR = 130 × (Scr/0.7)-0.219  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Female if ō0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.219  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Female if > 0.7 if ō0.8 eGFR = 130 × (Scr/0.7)-0.544  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Female if > 0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.544  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Male if ō0.9 if ō0.8 eGFR = 135 × (Scr/0.9)-0.144  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Male if ō0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.144  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Male if > 0.9 if ō0.8 eGFR = 135 × (Scr/0.9)-0.544  ʹ  (Scys/0.8)-0.323  ʹ(0.9961)Age
Male if > 0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.544  ʹ  (Scys/0.8)-0.778  ʹ(0.9961)Age
10.7.3. Adverse Event Grading for Kidney Safety Laboratory Abnorm alities
AE grading for decline in kidney function (ie, eGFR or eCrCl) wi ll be according to KDIGO
criteria.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 8410.8. Appendix 8: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs
•Marked sinus bradycardia (rate <40 bpm) lasting minutes.
•New PR interval prolongation >280 ms.
•New prolongation of QTcF to >480 ms (absolute) or by ≥60 ms fro m baseline.
•New-onset atrial flutter or fibrillation, with controlled ventr icular response rate: ie, 
rate <120 bpm.
•New-onset type I second-degree (Wenckebach) AV block of >30 sec onds’
duration.
•Frequent PVCs, triplets, or short intervals (<30 seconds) of cons ecutive 
ventricular complexes.
ECG Findings That May Qualify as SAEs
•QTcF prolongation >500 ms.
•New ST-T changes suggestive of myocardial ischemia.
•New-onset LBBB (QRS complex>120 ms).
•New-onset right bundle branch block (QRS complex>120 ms).
•Symptomatic bradycardia.
•Asystole:
•In awake, symptom -free participants in sinus rhythm, with docum ented 
periods of asystole ≥3.0 seconds or any escape rate <40 bpm, or w ith an 
escape rhythm that is below the AV node. 
•In awake, symptom -free participants with atrial fibrillation and  bradycardia 
with 1 or more pauses of at least 5 seconds or longer. 
•Atrial flutter or fibrillation, with rapid ventricular response  rate: rapid = rate 
>120 bpm.
•Sustained supraventricular tachycardia (rate >120 bpm) (“sustain ed” = short 
duration with relevant symptoms or lasting >1 minute).
•Ventricular rhythms >30 seconds’ duration, including idioventric ular rhythm (HR
<40 bpm), accelerated idioventricular rhythm (HR >40 bpm to <100 bpm), and 
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 85monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [su ch as
torsades de pointes]).
•Type II second -degree (Mobitz II) AV block.
•Complete (third -degree) heart block.
ECG Findings That Qualify as SAEs
•Change in pattern suggestive of new myocardial infarction.
•Sustained ventricular tachyarrhythmias (>30 seconds’ duration).
•Second- or third-degree AV block requiring pacemaker placement.
•Asystolic pauses requiring pacemaker placement.
•Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
•Ventricular fibrillation/flutter.
•At the discretion of the investigator, any arrhythmia classifie d as an adverse 
experience.
The enumerated list of major events of potential clinical conce rn are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator a nd Pfizer study team, and not to be 
considered as all-inclusive of what to be reported as AEs/SAEs.
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 8610.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may be used in th e protocol.
Abbreviation Term
Abs absolute
ADL activity/activities of daily living
ADME absorption, distribution, metabolism, and excretion
AE adverse event
AKI acute kidney injury
ALT alanine aminotransferase
ANOVA analysis of variance
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the curve
AUC inf area under the concentration-time curve from time 0 to infinit y
AUC last area under the concentration-time curve from 0 to time of last 
measurable concentration
AV atrioventricular
BA bioavailability
BE bioequivalence
BLQ below the limit of quantitation
BMI body mass index
BP blood pressure
BRAF B-RAF proto-oncogene, serine/threonine kinase
BRAFmtBRAF-mutated
CAP encorafenib formulated capsule
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Science s
CK creatine kinase
CKD-EPI chronic kidney disease - epidemiology
CL/F a pparent clearance of drug from eg, plasma
Cmax maximum observed concentration
CNS central nervous system
CO 2 carbon dioxide (bicarbonate)
COT cancer osaka thyroid
COVID-19 coronavirus disease 2019
CRAF COT and RAF-1
CRC colorectal cancer
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study Report
CT clinical trial
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 87Abbreviation Term
CTIS Clinical Trial Information System
CTMS Clinical Trial Management System
CV cardiovascular
CYP cytochrome P450
DCT data collection tool
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC data monitoring committee
DMID dosage material identification
DU dispensable unit
EC ethics committee
EC50 half-maximal response concentration
ECC emergency contact card
ECG electrocardiogram or electrocardiography
eCrCl estimated creatinine clearance
eCRF electronic case report form
EDB exposure during breastfeeding
E-DMC External Data Monitoring Committee
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EGFR epidermal growth factor receptor
EMA European Medicines Agency
EOT end of treatment
 
 
ERK extracellular signal- regulated kinase
eSAE electronic serious adverse event
EU European Union
EudraCT European Union Drug Regulating Authorities Clinical Trial s 
(European Clinical Trials Database)
FDA Food and Drug Administration
FSH follicle-stimulating hormone
F/U follow-up
G1 to G5 Grade (KDIGO eGFR category standardization)
GCP Good Clinical Practice
GERD gastroesophageal reflux disease
GGT gamma-glutamyl transferase
GLP good laboratory practice
HBcAb hepatitis B core antibody
HbsAb hepatitis B surface antibody
HbsAg hepatitis B surface antigen
PPDCCI
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 88Abbreviation Term
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HME hot-melt extrudate
HR heart rate
HRT hormone replacement therapy
Ht height
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IPAL Investigational Product Accountability Log
IPM investigational product manual
IR immediate release 
IRB Institutional Review Board
IRC internal review committee
IV intravenous(ly)
K Proportionality constant for Bedside and Modified Schwartz 
Equations (kidney function)
K2EDTA dipotassium ethylenediaminetetraacetic acid
K3EDTA tripotassium ethylenediaminetetraacetic acid
kel first-order elimination rate constant
KDIGO Kidney Disease Improving Global Outcomes
LBBB left bundle branch block
LFT liver function test
LLNA local lymph node assay
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
mCRC metastatic colorectal cancer
MCV mean corpuscular volume
MEK mitogen-activated protein kinase
MQI medically qualified individual
MTD maximum tolerated dose
N/A not applicable
Nab neutralizing antibodies
NRU neutral red u ptake
OAT organic anion transporter
OATP organic anion-transporting polypeptide
OCT organic cation transporte r
PCR polymerase chain reaction
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 89Abbreviation Term
PCRU Pfizer Clinical Research Unit
PD pharmacodynamic(s)
pERK phosphorylated ERK
pMEK phosphorylated MEK
P-gp P-glycoprotein
PI principal investigator
PK pharmacokinetic(s)
PPI proton- pump inhibitor
PSSA Pfizer’s Serious Adverse Event Submission Assistant
PT prothrombin time
PVC premature ventricular contraction/complex
QD once daily
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
QTL quality tolerance limit
qual qualitative
RAF rapidly accelerated fibrosarcoma
rBA relative bioavailability
RBC red blood cell
RNA ribonucleic acid
SADE serious adverse device effect
SAE serious adverse event
SAP Statistical Analysis Plan
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SC subcutaneous
SCL supply chain lead
Scr serum creatinine
Scys serum cystatin C
SoA schedule of activities
SOP standard operating procedure
SRSD Single Reference Safety Document
SUSAR Suspected Unexpected Serious Adverse Reaction
t½ terminal phase half-life
T3total triiodothyronine
TB tuberculosis 
Tbili total bilirubin
THC tetrahydrocannabinol
Tlast time of the last quantifiable concentration [time]
Tmax time to reach C max
TOC table of contents
UGT uridine 5’-diphospho-glucuronosyltransferase-
glucuronosyltransferase
ULN upper limit of normal
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 90Abbreviation Term
US United States
USADE unanticipated serious adverse device effect
USPI United States Prescribing Information
UTI urinary tract infection
Vz/F apparent volume of distribution for extravascular dosing
WBC white blood cell
WOCBP woman/women of childbearing potential
PPD
Encorafenib
Protocol C4221024Protocol Amendment 1, 27 June 2022
PFIZER CONFIDENTIAL
Page 9111. REFERENCES
1. Japan Guideline for Bioequivalence Studies of Generic Product s.
https://www.nihs.go.jp/drug/be-guide(e)/2020/GL1_BE_2020.pdf
2. Japan Guideline for Bioequivalence Studies for Formulation Ch anges of Oral Solid 
Dosage Formshttps://www.nihs.go.jp/drug/be-guide(e)/form/GL-E_120229_shohou .pdf 
3. Japan Guideline for Bioequivalence Studies for Different Oral  Solid Dosage Forms
https://www.nihs.go.jp/drug/be-guide(e)/GL-E_120229_zaikei.pdf
4. Li, X.Q., et al., Comparison of inhibitory effects of the pro ton pump-inhibiting drugs 
omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabep razole on human 
cytochrome P450 activities. Drug Metab Dispos, 2004. 32(8): p. 821-7.
5. Zvyaga, T., et al., Evaluation of six proton pump inhibitors as inhibitors of various 
human cytochromes P450: focus on cytochrome P450 2C19. Drug Met ab Dispos, 2012. 
40(9): p. 1698-711.
6. Marelli, S. and F. Pace, ParietÒ for the treatment of acid-re lated disorders. Expert Rev 
Gastroenterol Hepatol, 2012. 6(4): p. 423-35.
7. Shi, S. and U. Klotz, Proton pump inhibitors: an update of th eir clinical use and 
pharmacokinetics. Eur J Clin Pharmacol, 2008. 64(10): p. 935-51 .
8. Williams, M.P., et al., A placebo-controlled Study to assess the effects of 7-day dosing 
with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in 
healthy male subjects. Aliment Pharmacol Ther, 2000. 14(6): p. 691-9.
9. Hayato, S., et al., Dose-response relationships of rabeprazol e 5, 10, 20, and 40 mg once 
daily on suppression of gastric acid secretion through the nigh t in healthy Japanese 
individuals with different CYP2C19 genotypes. Eur J Clin Pharma col, 2012. 68(5): p. 
579-88.
10. Inker LA et al. N Engl J Med. 2021;385:1737-49.
PPD